ribavirin has been researched along with HIV Coinfection in 878 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 35 (3.99) | 18.2507 |
| 2000's | 410 (46.70) | 29.6817 |
| 2010's | 417 (47.49) | 24.3611 |
| 2020's | 16 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Pathania, S; Rawal, RK | 1 |
| Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Lu, CL; Wang, YK; Wang, YW | 1 |
| Berenguer, J; Carrero, A; Crespo, M; de Los Santos, I; Gómez, J; González-García, J; Guardiola, JM; Jiménez-Sousa, MÁ; Martínez, I; Resino, S; Vázquez-Morón, S; Vigón, L; Von Wichmann, MA; Yélamos, MB | 1 |
| Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ | 1 |
| Aguilar, P; Aldámiz-Echevarría, T; Andrade, RJ; Carnicer, F; Carrión, JA; Chimeno-Hernández, S; Delgado, M; Escarda, A; Espinosa, N; Estébanez, Á; Gallego, A; García-Buey, L; Hernández-Guerra, M; Hijona, L; Izquierdo, S; Jou, A; Lorente, S; Magaz, M; Manuel Sousa, J; Manzanares, A; Martín-Granizo, I; Mateos-Muñoz, B; Menéndez, F; Morán-Sánchez, S; Morano, L; Moreno-Planas, JM; Morillas, RM; Polo-Lorduy, B; Pulido, F; Rico, M; Rincón, D; Rodríguez, M; Rubín, Á; Salmerón, J; Sampedro, B; Sánchez Antolín, G; Vergara, M; Von-Wichmann, MÁ; Zozaya, JM | 1 |
| Carvalho, L; Daniels, E; Eveson, L; Foxton, M; Nelson, M; Pillai, S; Sellers, P; Whyte, R | 1 |
| Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S | 1 |
| Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX | 1 |
| Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL | 1 |
| Nordien, R; Sonderup, MW; Spearman, CW | 1 |
| Bellón, JM; Berenguer, J; Carrero, A; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; Hernández-Quero, J; Hontañón, V; Jiménez-Sousa, MA; Martínez, E; Navarro, J; Pérez-Latorre, L; Quereda, C; Resino, S; Santos, I; Sanz, J; Téllez, MJ; von Wichmann, MA | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ | 1 |
| Estévez Escobar, M; Gómez Torres, KM; Lozano Serrano, AB | 1 |
| Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K | 1 |
| Bai, L; Chen, L; Du, L; He, M; Kang, S; Li, C; Ma, F; Tang, H | 1 |
| Flisiak, R; Groth, M; Grubczak, K; Grzeszczuk, A; Hryniewicz, A; Kretowska-Grunwald, A; Moniuszko, M | 1 |
| Falade-Nwulia, O; Fried, MW; Nelson, DR; Segal, JB; Suarez-Cuervo, C; Sulkowski, MS | 1 |
| Brainard, DM; Chung, R; Fierer, DS; Hollabaugh, K; Hughes, M; Kim, A; Kiser, JJ; Macbrayne, C; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Symonds, B | 1 |
| Fialho, R; Harrison, N; Pereira, M; Rusted, J; Whale, R | 1 |
| Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
| Callard, RE; Klein, NJ; Lewis, J; Majekodunmi, AO; Malyuta, R; Thorne, C; Volokha, A | 1 |
| Álvarez, B; Benito, JM; Cabello, A; García, M; García-Samaniego, J; Górgolas, M; Madejón, A; Martín-Carbonero, L; Rallón, N | 1 |
| Akhavan, S; Calin, R; Demeret, S; Jaspard, M; Katlama, C; Mallet, V; Peytavin, G; Pourcher, V; Poynard, T; Roque-Afonso, AM; Thibault, V; Todesco, E | 1 |
| GeurtsvanKessel, CH; Hullegie, SJ; Ramakers, C; Rijnders, BJA; van der Eijk, AA | 1 |
| Altice, FL; Barnard, T; Filippovych, S; Mazhnaya, A; Meteliuk, A; Zelenev, A | 1 |
| Casari, S; Castelli, F; Cattaneo, C; Chirico, C; Festa, E; Grecchi, C; Izzo, I; Odolini, S; Spinetti, A; Zaltron, S; Zanotti, P | 1 |
| Ballard, C; Cachay, ER; Colwell, B; Hicks, C; Mathews, WC; Torriani, F | 1 |
| Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH | 1 |
| Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E | 1 |
| Carlton-Smith, C; Chung, RT; Holmes, JA; Kim, AY; Lauer, GM; Lidofsky, A; Naggie, S | 1 |
| Agarwal, K; Carey, I; Lampejo, T | 1 |
| Apornpong, T; Avihingsanon, A; Burger, DM; Chaiyahong, P; Chittmittraprap, S; Colbers, A; Cuprasitrut, T; de Kanter, CTMM; Khemnark, S; Smolders, EJ; Tangkijvanich, P; Thammajaruk, N | 1 |
| Garcia-Broncano, P; Genebat, M; Harrington, S; Hua, S; Leal, M; Lichterfeld, M; Marchetti, G; Negron, J; Resino, S; Ruiz-Mateos, E; Tse, S; Vigano, S; Yu, XG; Zhengyu, O | 1 |
| Morikawa, K; Ogawa, K; Sakamoto, N; Suda, G | 1 |
| Amador, C; Carmena, J; Flores, J; Galindo, MJ; García-Deltoro, M; Masiá, M; Mínguez, C; Montero, M; Ortega, E; Reus, S | 1 |
| Scott, LJ | 1 |
| Collado, A; de Los Santos, I; Macías, J; Mancebo, M; Merino, D; Morano-Amado, LE; Palacios, R; Pérez, AB; Pérez-Pérez, M; Pineda, JA; Ríos, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Andreoni, M; Antinori, A; Bigoni, S; Boffa, N; Borghi, V; Bovis, F; Bruno, R; Cacopardo, B; Cattelan, A; Chirianni, A; D'Arminio Monforte, A; Di Biagio, A; Di Perri, G; Giacometti, A; Gori, A; Gubertini, G; Hasson, H; Mastroianni, C; Milazzo, L; Montagnani, F; Nicolini, LA; Niero, F; Parruti, G; Pasquazzi, C; Puoti, M; Saracino, A; Segala, D; Sollima, S; Spinetti, A; Taliani, G; Taramasso, L; Teti, E; Vullo, V | 1 |
| Abbott, JC; Boesecke, C; Jagjit Singh, GK; Kaye, S; McClure, MO; Nelson, M; Rockstroh, J | 1 |
| Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM | 1 |
| Berg, CP; Berg, T; Blessin, U; Engelmann, C; Grottenthaler, JM; Harrer, E; Hinterleitner, C; Lauer, UM; Malek, NP; Pathil, A; Sarrazin, C; Scholten, S; Schott, E; Seybold, U; Spengler, U; Steurer, M; Stremmel, W; von Hahn, T; Wedemeyer, H; Welker, MW; Werner, CR | 1 |
| Clark, PJ; Clement, M; Dubois, L; Himmel, T; Kottilil, S; Lucas, JE; Lusk, S; Moseley, MA; Naggie, S; Osinusi, A; Patel, K; Thompson, WJ | 1 |
| Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M | 1 |
| Sulkowski, MS | 6 |
| Bischoff, J; Rockstroh, JK | 1 |
| Bair, MJ; Chen, CH; Chen, CK; Chen, CP; Cheng, CH; Cheng, CY; Cheng, SH; Zou, H | 1 |
| Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V | 1 |
| Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
| Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Díez, C; Fanciulli, C; Garcia-Broncano, P; Jiménez-Sousa, MA; Medrano, LM; Miralles, P; Pérez-Latorre, L; Resino, S | 1 |
| Djauzi, S; Gani, RA; Harimurti, K; Ibrahim, F; Imannuel, S; Kurniawan, J; Nafrialdi, N | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| de los Santos-Gil, I; Gea, I; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merchante, N; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F; Torres-Cornejo, A | 1 |
| Anthony, D; Asaad, R; Debernardo, R; Funderburg, NT; Harding, CV; Hardy, GA; Jiang, W; Lederman, MM; Mudd, J; Pilch-Cooper, HA; Rabin, RL; Rodriguez, B; Schacker, T; Sieg, S | 1 |
| Cohn, J; Piot, P; Swan, T; von Schoen-Angerer, T | 1 |
| Bani-Sadr, F; Carrieri, P; Dabis, F; Loko, MA; Marchou, B; Morlat, P; Neau, D; Pambrun, E; Salmon, D; Winnock, M | 1 |
| Colson, P; Gérolami, R; Hajji, H; Moreau, J; Solas, C | 1 |
| Castelnovo, D; Fisher, M; Gilleece, Y; Keller, M; Mistry, H; Tibble, J; Webster, DP; Wojcikiewicz, T | 1 |
| Berg, T; Buggisch, P; Cornberg, M; Deterding, K; Diepolder, H; Feyerabend, S; Galle, PR; Großhennig, A; Grüner, N; Hinrichsen, H; Jung, MC; Koch, A; Lüth, S; Malek, N; Manns, MP; Potthoff, A; Rogalska-Taranta, M; Schlaphoff, V; Spengler, U; Wedemeyer, H; Wiegand, J | 1 |
| Cahn, P; Gun, A; Laufer, N; Ojeda, D; Quarleri, J; Sede, M | 1 |
| Benito, JM; Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Rallón, N; Resino, S; Restrepo, C; Soriano, V | 2 |
| Casado, JL; Dronda, F; Hermida, JM; Moreno, A; Moreno, S; Navas, E; Pérez-Elías, MJ; Quereda, C; Royuela, A; Serrano-Villar, S | 1 |
| Avellón, A; Barreiro, P; Cifuentes, C; Echevarría, JM; Macías, J; Martín-Carbonero, L; Neukam, K; Pineda, JA; Soriano, V; Vargas, J | 1 |
| Abeleira, M; Diz, P; Eirea, M; Feijoo, J; Limeres, J; Ocampo, A; Ramos, I | 1 |
| Bonnet, F; Hessamfar, M; Michaux, C; Morlat, P; Randrianasolo, D; Vandenhende, MA | 1 |
| Adda, N; Adiwijaya, B; Bsharat, M; Dieterich, DT; Garg, V; Gharakhanian, S; Girard, PM; Henshaw, J; Mahnke, L; McCallister, S; Rockstroh, JK; Rubin, RA; Sherman, KE; Soriano, V; Sulkowski, MS | 1 |
| Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M | 1 |
| Barreiro, P; Camacho, A; Caruz, A; Cifuentes, C; Di Lello, FA; García-Rey, S; Macias, J; Neukam, K; Pineda, JA; Rallon, NI; Rivero, A; Rivero-Juarez, A; Soriano, V | 1 |
| Belleli, D; Davis, AK; Kemp, W; McCarthy, P; Northcott, MJ; Ong, WL; Street, A; Tran, H; Walsh, M | 1 |
| Branch, AD; Chung, RT; Glesby, MJ; Hollabaugh, K; Kang, M; Wyatt, CM | 1 |
| Naggie, S; Osinusi, A | 1 |
| Cooper, C; Fainboim, H; Greaves, W; Howe, AY; Mak, C; Mallolas, J; Pol, S; Rivero, A; Sklar, P; Slim, J; Sulkowski, M; Thompson, S; Wahl, J; Wenning, L | 1 |
| Mendes-Correa, MC; Núñez, M | 1 |
| Bregigeon, S; Colson, P; Poizot-Martin, I; Solas, C; Tamalet, C; Tourres, C | 1 |
| Benito, JM; Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Medrano, J; Miralles, P; Rallón, N; Resino, S; Soriano, V | 1 |
| Bergin, C; Farrell, G; Gardiner, CM; Keane, C; O'Shea, D; Peck-Radosavljevic, M; Reiberger, T | 1 |
| Baumgarten, A; Boesecke, C; Grzeszczuk, A; Mandorfer, M; Meyer-Olson, D; Neukam, K; Payer, BA; Peck-Radosavljevic, M; Pineda, JA; Puoti, M; Reiberger, T; Rivero, A; Rockstroh, JK; Trauner, M; Zangerle, R | 1 |
| Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL | 1 |
| Battegay, M; Beniowski, M; Grint, D; Jevtovic, D; Kirk, O; Lundgren, JD; Mocroft, A; Peters, L; Pradier, C; Rockstroh, JK; Schwarze-Zander, C; Soriano, V | 1 |
| Amendola Pires, MM; Barcaui, HS; Barroso, PF; Brandão-Mello, CE; May, SB; Tavares, GC | 1 |
| Aichelburg, MC; Breitenecker, F; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scheiner, B; Trauner, M | 1 |
| Camacho, A; Caruz, A; Gutierrez-Valencia, A; Lopez-Cortes, LF; Martinez-Dueñas, L; Rivero, A; Rivero-Juarez, A; Ruiz-Valderas, R; Torre-Cisneros, J; Torres-Cornejo, A | 1 |
| Baumgarten, A; Boesecke, C; Ingiliz, P; Krämer, B; Mauss, S; Nattermann, J; Nischalke, HD; Rockstroh, JK; Spengler, U; Stellbrink, HJ; Voigt, E | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Peytavin, G; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Bichoupan, K; Branch, A; Brinkley, S; Dieterich, D; Martel-Laferrière, V; Perumalswami, P; Posner, S; Schiano, T; Stivala, A; Sulkowski, M | 1 |
| Cai, Z; Deng, H; Ji, F | 1 |
| Cabezas, J; Crespo, J; Luis Calleja, J; Selmo, J | 1 |
| Macías, J; Rivero, A | 1 |
| Camacho, A; López-Cortés, LF; Marquez, M; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rivero-Juarez, A; Téllez, F | 1 |
| Aparicio, E; Clotet, B; Franco, S; Martinez, MA; Parera, M; Tural, C | 1 |
| Chiari, E; Cocca, G; Moioli, MC; Morreale, M; Orso, M; Panzeri, C; Puoti, M; Rossotti, R; Travi, G | 1 |
| Beste, LA; Green, PK; Ioannou, GN; Scott, JD; Yang, Y | 1 |
| Carpio-Pedroza, JC; Cruz-Rivera, M; Escobar-Gutiérrez, A; Fonseca-Coronado, S; Larouche, A; Martinez-Guarneros, A; Ruiz-Tovar, K; Soudeyns, H; Vazquez-Chacon, CA; Yamasaki, LH | 1 |
| Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Bon, D; Cai, SY; Haagmans, B; Herrmann, E; Kottilil, S; Lee, YJ; Lempicki, R; Masur, H; Nelson, A; Osinusi, A; Polis, M; Poonia, S; Shivakumar, B; Sneller, M; Wood, B | 1 |
| Kottilil, S; Lee, YJ; Murphy, A; Shivasabesan, G; Siebenlist, U; Suffredini, AF; Vazquez, E; Wang, H; Young, HA; Zhang, X | 1 |
| Jiangrong, W; Jing, L; Yingying, L | 1 |
| Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Sánchez-Parra, C; Soriano, V; Treviño, A; Vispo, E | 1 |
| Bhagani, S; Rockstroh, JK | 1 |
| Barluenga, E; Clotet, B; Jou, A; López, JJ; Muga, R; Ojanguren, I; Planas, R; Sanmartín, R; Sanvisens, A; Tor, J; Tural, C; Videla, S | 1 |
| Barreiro, P; Camacho, A; Labarga, P; Macias, J; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juarez, A; Soriano, V; Torre-Cisneros, J | 1 |
| Berg, RK; Buzon, MJ; Ferrando-Martinez, S; Leal, M; Lichterfeld, M; Ruiz-Mateos, E; Shaw, A; Sun, H; Yu, XG | 1 |
| Applegate, T; Cherepanov, V; Dore, GJ; Feld, JJ; Grebely, J; Hellard, M; Kaldor, JM; Lloyd, AR; Matthews, GV; Petoumenos, K; Sherker, A; Yeung, B | 1 |
| Casado, JL; Martí-Belda, P; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C | 1 |
| Aichelburg, MC; Breitenecker, F; Mandorfer, M; Obermayer-Pietsch, B; Payer, BA; Peck-Radosavljevic, M; Puoti, M; Reiberger, T; Rieger, A; Trauner, M; Zangerle, R | 1 |
| Cai, WP; Hu, FY; Lan, Y; Liu, B; Tang, XP; Xu, M | 1 |
| Girón-Gonzalez, JA; Lopez-Cortes, LF; Pineda, JA; Rivero, A; Rivero-Juarez, A | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Goujard, C; Hessamfar, M; Krastinova, E; Perronne, C; Pol, S; Yazdanpanah, Y | 1 |
| Abad-Molina, C; Gutierrez-Valencia, A; Jimenez-Jimenez, L; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Kang, W; Lu, Y; Sun, Y; Tong, HI | 1 |
| Furusyo, N; Hayashi, J; Hiramine, S; Ikezaki, H; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Shimizu, M; Takayama, K; Toyoda, K | 1 |
| Alvarez, H; de la Llana, FG; Domingo, P; Genebat, M; Guardiola, JM; Hernández-Quero, J; Leal, M; Lluch, JF; Marín, J; Mariño, A; Martínez, L; Martínez-Madrid, O; Martínez-Pérez, MA; Ruiz-Mateos, E; Sánchez-Villegas, J; Vera, F | 1 |
| Adams-Huet, B; Bedimo, R; Holodniy, M; Jain, MK; Kushner, LE; Li, X; Terekhova, D | 1 |
| Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P | 1 |
| Aldámiz, T; Benito, JM; Berenguer, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Rallón, N; Resino, S; Restrepo, C; Soriano, V | 1 |
| Angarano, G; Bruno, R; Capetti, A; Caputo, A; Cariti, G; Carosi, G; Galli, M; Gulminetti, R; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Raise, E; Ravasio, V; Verucchi, G | 1 |
| Barin, B; Barnes, D; Curry, M; Dove, L; Johl, J; Millis, M; Peters, M; Poordad, F; Reddy, KR; Regenstein, F; Roland, M; Schiano, T; Schiff, E; Shaikh, O; Shetty, K; Stock, P; Terrault, N | 1 |
| Bailly, F; Chiarello, P; Gagnieu, MC; Hatu, G; Livrozet, JM; Maynard, M; Miailhes, P; Parant, F; Pourcelot, E; Pradat, P; Zoulim, F | 1 |
| Assoumou, SA; Barter, DM; DiLorenzo, M; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Salomon, JA; Schackman, BR; Weinstein, MC | 1 |
| Antoine, SL; Mathes, T; Pieper, D | 1 |
| Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Pinilla, J; Plaza, Z; Soriano, V; Vispo, E | 1 |
| Bagnarelli, P; Capobianchi, MR; Ferreri, ML; Galli, C; Garbuglia, AR; Monachetti, A; Sabatini, R | 1 |
| Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Aichelburg, MC; Boesecke, C; Lang, G; Mandorfer, M; Niederecker, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R; Trauner, M | 1 |
| Abdelrahman, T; Hughes, J; Main, J; McLauchlan, J; Thomson, E; Thursz, M | 1 |
| Cooper, CL; Klein, MB | 1 |
| Angeli, E; Caputo, A; Cattelan, AM; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G | 1 |
| James, P; Win, LL; Wong, DK | 1 |
| Barrett, L; Kottilil, S; Masur, H; Odigie, M; Osinusi, A; Polis, MA; Suffredini, AF; Townsend, K; Wang, H | 1 |
| Bani-Sadr, F; Brodard, V; Ehrhard, F; Hentzien, M; Izopet, J; Lambert, D; Lebrun, D; Nguyen, Y; Peron, JM; Robbins, A; Tabary, T | 1 |
| Abdel-Hamid, M; Albert, ML; Bonnard, P; Casrouge, A; Duffy, D; El-Daly, M; Fontanet, A; Hézode, C; Izopet, J; Laird, ME; LeFouler, L; Mallet, V; Mamdouh, R; Mohamed, MK; Mohsen, A; Pawlotsky, JM; Pol, S; Rafik, M; Renard, P; Rosa, I; Soulier, A | 1 |
| Camacho, A; Gordon, A; López-Cortés, LF; Pineda, JA; Rivero, A; Rivero-Juarez, A; Ruiz-Valderas, R; Torre-Cisneros, J; Torres-Cornejo, A; Viciana, P | 1 |
| Gatanaga, H; Igari, T; Ishikane, M; Kikuchi, Y; Masaki, N; Nozaki, Y; Oka, S; Tsukada, K; Watanabe, K; Yanase, M | 1 |
| Begovac, J | 2 |
| Lim, TH; Pearlman, BL | 1 |
| Kared, H; Klein, MB; Saeed, S; Shoukry, NH | 1 |
| Corchado, S; Girón-González, JA; López-Cortés, LF; Márquez-Coello, M; Rivero, A; Rivero-Juárez, A; Torres-Cornejo, A | 1 |
| Arends, JE; Baumgarten, A; Boesecke, C; Hoepelman, AI; Ingiliz, P; Rockstroh, JK; Schwarze-Zander, C; Stellbrink, HJ; Strassburg, CP; van Assen, S; Wasmuth, JC | 1 |
| Bruno, R; Capetti, A; Cariti, G; Galli, M; Iannacone, C; Nasta, P; Palmieri, G; Puoti, M; Raise, E; Ravasio, V | 1 |
| Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z | 1 |
| Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Martínez, P; Miguel Benito, J; Miralles, P; Rallón, N; Resino, S; Soriano, V | 1 |
| Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Soriano, V | 1 |
| Blanco, JL; Gatell, JM; González-Cordón, A; Laguno, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Monteiro, P; Pérez, I; Rojas, JF; Torres, B | 1 |
| Abradelo, M; Agüero, F; Aguilera, V; Antela, A; Barcena, R; Bernal, C; Castells, L; de la Rosa, G; Del Campo, S; Esteban-Mur, JI; Fernandez, JR; González-García, J; Laguno, M; Manzardo, C; Miro, JM; Montero, JL; Olivares, S; Perez, I; Rimola, A; Rodriguez, M; Salcedo, M; Suarez, F; Valdivieso, A; Xiol, X | 1 |
| Aboulker, JP; Aumaitre, H; Batisse, D; Bertucci, I; Braun, J; Chevaliez, S; Cotte, L; de Truchis, P; Gervais, A; Lacombe, K; Lascoux-Combe, C; Michelet, C; Molina, JM; Morlat, P; Neau, D; Rosa, I; Sogni, P; Valantin, MA; Vincent, C; Vittecoq, D | 1 |
| Rockstroh, JK | 3 |
| Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Montes, M; Quereda, C; Santos, I; Sanz, J; Téllez, MJ; Von Wichmann, MA; Zamora, FX | 1 |
| De La Rosa, G; Dieterich, D; Gutiérrez, F; Jenkins, A; Jessner, W; Klein, MB; Lenz, O; Orkin, C; Ouwerkerk-Mahadevan, S; Peeters, M; Reynes, J; Rockstroh, JK; Shukla, U; Tambuyzer, L | 1 |
| Aichelburg, MC; Grabmeier-Pfistershammer, K; Lang, G; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Briz, V; Carrero, A; Diez, C; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Briz, V; Carrero, A; Diez, C; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F; Vázquez, S | 1 |
| Amadasi, S; Castelli, F; Cerini, C; Giralda, M; Nasta, P; Odolini, S | 1 |
| Abdel-Mohsen, M; Danesh, A; Deng, X; Günthard, HF; Jacobs, ES; Ledergerber, B; Liegler, T; Norris, PJ; Pillai, SK; Rauch, A; Wong, JK | 1 |
| Castro, JA; Cifuentes, C; González-Candelas, F; Homar, F; López-Labrador, FX; Matas, M; Moya, A; Payeras, A; Picornell, A; Ramon, C | 1 |
| Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Carrero, A; Diez, C; García-Alvarez, M; García-Broncano, P; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F; Vázquez-Morón, S | 1 |
| Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Costa e Silva, FV; Jardim, FN; Mosegui, GB; Peregrino, AA; Rodrigues, MP; Vianna, CM | 1 |
| Bagaglio, S; Della Torre, L; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Uberti-Foppa, C | 1 |
| Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E | 1 |
| Cornberg, M; Manns, MP | 1 |
| de los Santos-Gil, I; Haubitz, S; Ingiliz, P; Lutz, T; Márquez, M; Mira, JA; Munteanu, D; Neukam, K; Pineda, JA; Rauch, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S | 1 |
| Beste, LA; Green, PK; Ioannou, GN | 1 |
| Aboulker, JP; Barrail-Tran, A; Chevaliez, S; Cotte, L; Fournier, I; Lacombe, K; Molina, JM; Taburet, AM; Valantin, MA; Vincent, C | 1 |
| Diego, R; Giampaolo, Q; Marco, R; Sara, B; Vasilij Benatti, S | 1 |
| Modi, R; Saab, S | 1 |
| Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Becker, B; Berden, FA; Burger, DM; Colbers, AP; de Kanter, CT; de Knegt, RJ; Dofferhoff, AS; Drenth, JP; Grintjes-Huisman, KJ; Koning, L; Rockstroh, JK; Roukens, MM; Wasmuth, JC | 1 |
| Brainard, D; Gaggar, A; Gonzalez, M; Kirby, B; McHutchison, JG; Rodriguez-Orengo, J; Rodriguez-Torres, M; Shen, G; Svarovskaia, E; Symonds, WT | 1 |
| Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M | 1 |
| Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L | 1 |
| Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX | 1 |
| Kim, AY; Naggie, S | 1 |
| Angeli, E; Caputo, A; Carosi, G; Cattelan, AM; Giralda, M; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G | 1 |
| Arastéh, K; Bhagani, S; Dieterich, D; Guardiola, JM; Ingiliz, P; Jain, MK; Kort, J; Laguno, M; Manero, M; Nelson, M; Rockstroh, JK; Soriano, V; Stern, JO; Tural, C; Vinisko, R | 1 |
| Angarano, G; Bartolomeo, N; Bruno, G; Fasano, M; Ladisa, N; Maggi, P; Monno, L; Saracino, A; Volpe, A | 1 |
| Benito, JM; Berenguer, J; Cosín, J; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Pineda-Tenor, D; Rallón, N; Resino, S; Retana, D; Soriano, V | 1 |
| Curto, J; Di Yacovo, S; Ferrer, E; Imaz, A; Podzamczer, D; Saumoy, M; Van den Eynde, E; Vila, A | 1 |
| Häggblom, A; Nowak, P; Nyström, J; Stenkvist, J; Weiland, O | 1 |
| Ben-Marzouk-Hidalgo, OJ; Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Carlsson, T; Hörnfeld, E; Lindahl, K; Parke, Å; Schvarcz, R; Ståhle, L; Weiland, O | 1 |
| Cai, WP; Gao, QS; Gao, YQ; Jiao, YM; Li, HJ; Li, LH; Weng, WJ; Wu, H; Zhu, WJ | 1 |
| Bañares, R; Berenguer, J; Catalina, MV; López, JC; Miralles, P; Pérez-Latorre, L; Rincón, D; Sánchez-Conde, M | 1 |
| Brown, A; Habibi, MS; Selvapatt, N | 1 |
| Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M | 1 |
| Agrawal, S; Kwo, PY | 1 |
| Chen, TY; Jain, MK | 1 |
| Cope, R; Faulds, S; Glowa, T; Pickering, A; Prasad, R; Veldkamp, P | 1 |
| Barcan, LA; Gadano, AC; Galdame, OA; Marciano, S | 1 |
| Baldelli, S; Cattaneo, D; Gervasoni, C; Milazzo, L; Peri, AM; Rizzardini, G | 1 |
| Bruneau, J; Deterding, K; Dore, GJ; Doyle, JS; Grebely, J; Hellard, ME; Kim, AY; Lloyd, AR; Manns, MP; Matthews, G; McGovern, BH; Morris, MD; Page, K; Rice, TM; Sacks-Davis, R; Spelman, T; Wedemeyer, H | 1 |
| Burger, DM; de Kanter, CT; Deenen, MJ; Dofferhoff, AS; Drenth, JP; Fleuren, HW; Gisolf, EH; Grintjes-Huisman, KJ; Koopmans, PP; van der Ven, AJ | 1 |
| Collado, A; de los Santos-Gil, I; Girón-González, JA; López-Cortés, LF; Macías, J; Merino, D; Mira, JA; Neukam, K; Ojeda-Burgos, G; Pérez-Pérez, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F; Torres-Cornejo, A | 1 |
| Castro-Iglesias, A; Cid, P; Macías, J; Martínez-Marcos, F; Mena, A; Merchante, N; Merino, MD; Monje-Agudo, P; Neukam, K; Ortega-González, E; Pernas, B; Pineda, JA; Real, LM; Rivero, A; Rivero-Juárez, A | 1 |
| Anagnostopoulos, A; Aouri, M; Böni, J; Braun, DL; Decosterd, L; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Müllhaupt, B; Rauch, A; Weber, R | 1 |
| Abad-Fernández, M; Casado, JL; Dronda, F; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Vallejo, A | 1 |
| Ambrosioni, J; Bernasconi, E; Bregenzer, A; Cavassini, M; Kovari, H; Ledergerber, B; Müller, D; Rauch, A; Rotger, M; Russmann, S; Speck, RF; Stöckle, M; Velli, P | 1 |
| Antón, JJ; Caylà, JA; de Juan, J; Faraco, I; Marco, A; Saíz de la Hoya, P; Trujols, J | 1 |
| Arends, JE; Brinkman, K; Hoepelman, AI; Kortmann, W; Posthouwer, D; Reiss, P; Richter, C; Schinkel, J; Smit, C; van Assen, S; van der Ende, M; van der Meer, JT; van der Valk, M | 1 |
| Farfour, E; Hillaire, S; Kahn, JE; Peytavin, G; Sené, T; Zucman, D | 1 |
| Ayoub, WS; Lutchman, GA; Nguyen, MH; Nguyen, NH; Yee, BE; Yip, B; Zhang, B | 1 |
| Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G | 1 |
| Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C | 1 |
| Babudieri, S; Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Magni, C; Martinelli, C; Menzaghi, B; Nicolini, LA; Parruti, G; Quirino, T; Ricci, E; Salomoni, E; Vichi, F | 1 |
| Wyles, DL | 1 |
| Baumgarten, A; Bhagani, S; Boesecke, C; Guiguet, M; Ingiliz, P; Lutz, T; Mauss, S; Nelson, M; Page, E; Reiberger, T; Rockstroh, JK; Stellbrink, HJ; Valantin, MA; Vogel, M; Voigt, E | 1 |
| Durant, J; Girard, PM; González-García, J; Grinsztejn, B; Horban, A; Janssen, K; Lathouwers, E; Montes, ML; Nelson, M; Ortega-Gonzalez, E; Ouwerkerk-Mahadevan, S; Rivero, A; Sasadeusz, J; Witek, J; Zakharova, N | 1 |
| Azzola, E; Boldrini, A; Bruzzone, B; Cenderello, G; De Leo, P; Di Biagio, A; Grasso, A; Icardi, G; Lorusso, C; Nicolini, LA; Prinapori, R; Rappazzo, E; Sartini, M; Setti, M; Sticchi, L; Valle, C | 1 |
| Bedimo, R; Bhattacharya, D; Brown, TT; Evans, C; Hollabaugh, K; Kang, M; McComsey, G; Overton, ET; Taiwo, B; Tebas, P | 1 |
| Aldámiz-Echevarria, T; Benito, JM; Berenguer, J; Diez, C; Fernández-Rodríguez, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Soriano, V | 1 |
| Clark, S; Cooke, GS; Gellissen, R; Irving, W; Main, J; Padam, P; Thomson, E | 1 |
| Andolina, A; Bagaglio, S; Di Serio, C; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Porrino, L; Trentini, F; Uberti-Foppa, C | 1 |
| Blanco, J; Clotet, B; Crespo, M; Gómez-Mora, E; Jou, A; Martinez-Picado, J; Montaner, LJ; Morón-López, S; Navarro, J; Ouchi, D; Pérez, M; Puertas, MC; Salgado, M; Tural, C; Urrea, V | 1 |
| Bani-Sadr, F; Dabis, F; Gilbert, C; Loko, MA; Morlat, P; Neau, D; Rosenthal, E; Salmon, D; Simon, A; Valantin, MA; Wittkop, L | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K | 1 |
| Chen, DS; Chen, PJ; Hsieh, SM; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Lo, YC; Sheng, WH; Su, TH; Sun, HY; Yang, HC | 1 |
| Delgado, M; López-Cortés, LF; Macías, J; Ojeda-Burgos, G; Pineda, JA; Recio, E; Ríos, MJ; Rivero-Juárez, A; Téllez, F | 1 |
| Busuttil, RW; Cheng, EY; Holt, CD; Saab, S | 1 |
| Aichelburg, MC; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Akamatsu, N; Arita, J; Hasegawa, K; Kaneko, J; Kokudo, N; Maki, H; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Tsukada, K | 1 |
| Dore, GJ; Martinello, M | 1 |
| Cope, R; Faulds, S; Glowa, T; McMahon, D; Prasad, R | 1 |
| Andersohn, F; Claes, AK; Kulp, W; Mahlich, J; Rockstroh, JK | 1 |
| Cooke, GS; Hill, A; Riley, RD; Saleem, J; Simmons, B | 1 |
| Aldamiz-Echevarria, T; Benito, JM; Berenguer, J; Carrero, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Restrepo, C; Soriano, V; Vazquez-Morón, S | 1 |
| Ackerman, P; Kalsekar, A; Kelley, C; Mu, F; Peeples, M; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Benhaourech, S; Borentain, P; Bregigeon, S; Colson, P; Darque, A; Gaubert, MR; Habib, G; Laugier, D; Maille, B; Renard, S; Salaun, E | 1 |
| Amorosa, VK; Dou, D; Kang, M; Kottilil, S; Lee, YJ; Matining, R; Osinusi, A; Peters, MG; Petersen, T; Umbleja, T; Wang, C; Zhang, X | 1 |
| Camacho, A; Cuenca, F; Frias, M; Gonzalez, R; Gordon, A; Manzanares-Martín, B; Peña, J; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Rodriguez-Cano, D | 1 |
| Cooper, C; Gill, J; Hull, M; Klein, MB; Moqueet, N; Platt, RW | 1 |
| Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G | 1 |
| Herbst, H; Ingiliz, P; Mayr, C; Obermeier, M; Pischke, S; Polywka, S | 1 |
| Belyakov, NA; Kizlo, SN; Mednikov, RV; Rabinovich, VI; Sokolov, AA | 1 |
| Alric, L; Bellissant, E; Bourlière, M; Carrieri, P; Colson, P; Garraffo, R; Ghosn, J; Halfon, P; Molina, JM; Naqvi, A; Piroth, L; Poizot-Martin, I; Renault, A; Solas, C | 1 |
| Cai, WP; Chen, XJ; He, Y; Hu, FY; Ke, YC; Lan, Y; Li, LH; Tang, XP | 1 |
| Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA | 1 |
| Abutidze, A; Bolokadze, N; Chkhartishvili, N; Sharvadze, L; Tsertsvadze, T | 1 |
| Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C | 1 |
| Bocquier, A; Carrieri, MP; Dabis, F; Esterle, L; Marcellin, F; Miailhes, P; Poizot-Martin, I; Protopopescu, C; Salmon-Ceron, D; Spire, B; Wittkop, L | 1 |
| Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC | 1 |
| Anthony, DD; Butt, AA; Funderburg, NT; Judge, CJ; Kang, M; Landay, AL; Lederman, MM; Sandberg, JK; Sherman, KE | 1 |
| Neumaier, J | 1 |
| Alric, L; Aumaître, H; Bani-Sadr, F; Billaud, E; Bouchaud, O; Boué, F; Chas, J; Dabis, F; Dominguez, S; Esterle, L; Gervais, A; Gilbert, C; Goujard, C; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Morlat, P; Neau, D; Piroth, L; Poizot-Martin, I; Rosenthal, E; Salmon, D; Simon, A; Sogni, P; Valantin, MA; Vittecoq, D; Wittkop, L; Zucman, D | 1 |
| Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Bayer, J; Gardner, EM; Johnson, S; Langness, J; Rogers, M; Rowan, SE; Smith, L | 1 |
| Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R | 1 |
| Ceccherini-Silberstein, F; Craxì, A; Perno, CF; Petta, S; Viganò, M | 1 |
| Agüero, F; Ambrosioni, J; Costa, J; Forner, A; Laguno, M; Lligoña, A; Londoño, MC; Manzardo, C; Miró, JM; Moreno, A; Rimola, A; Ruiz, P | 1 |
| Castelli, F; Di Filippo, E; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Gagliardini, R; Gori, A; Maggiolo, F; Pan, A; Postorino, MC; Prosperi, M; Quiros Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
| Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K | 1 |
| De Almeida, PR; De Leon, LB; De Mattos, AA; Feltrin, AA; Kliemann, DA; Pacheco, LS; Tovo, CV | 1 |
| Greig, SL | 1 |
| Carrero, A; Cervantes, M; Cifuentes, C; Cruceta, A; de Lazzari, E; Deig, E; Gómez-Sirvent, JL; Guardiola, JM; Jou, A; Laguno, M; López-Calvo, S; Mallolas, J; Martínez-Rebollar, M; Montes, ML; Murillas, J; Navarro, J; Pineda, JA; Ruiz-Mesa, JD; Tapiz, A; Van den Eynde, E; Veloso, S; Von Wichmann, MA | 1 |
| Ingiliz, P; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, JK; Van der Valk, M; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF | 1 |
| Bräu, N; Dieterich, DT; Miller, TR; Rivera-Mindt, M; Stivala, A; Weiss, JJ | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J | 1 |
| Aherfi, S; Brouqui, P; Colson, P; Dhiver, C; Meddeb, L; Menard, A; Mokhtari, S; Ravaux, I; Stein, A; Tissot-Dupont, H | 1 |
| Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A | 1 |
| Barbati, ZR; Dieterich, DT; El Sayed, A; Fierer, DS; Foster, AL; Morey, T; Turner, SS | 1 |
| Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Ackerman, P; Berenguer, J; Cheinquer, H; Côté, P; Dieterich, D; Eley, T; Fessel, WJ; Gadano, A; Hernandez, D; Hughes, E; Lazzarin, A; Liu, Z; Matthews, G; McPhee, F; Mendez, P; Molina, JM; Moreno, C; Noviello, S; Pineda, JA; Pulido, F; Rivero, A; Rockstroh, J; Sulkowski, MS; Zakharova, N | 1 |
| Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y | 1 |
| Conway, B; Lazzarin, A; Luetkemeyer, A; Molina, JM; Nelson, M; Portsmouth, S; Romanova, S; Rubio, R; Srinivasan, S; Xu, D | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Pol, S; Soriano, V | 1 |
| Cheng, D; Chu, Y; Liu, E; Xue, X; Yang, H; Yu, H; Zhao, S | 1 |
| Collado, A; Crespo, M; Esteban, JI; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Van den Eynde, E | 1 |
| Barreiro, P; López-Cortes, LF; Maida, I; Martín-Carbonero, L; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rodríguez-Nóvoa, S; Santos, I; Soriano, V; Vispo, E | 1 |
| Arends, JE; Hoepelman, AI; Mudrikova, T; Schaar, CG; Schrover, IM | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Driss, H; Goderel, I; Lapidus, N; Lunel-Fabiani, F; Morand, P; Perronne, C; Pol, S; Rosenthal, E; Simon, A | 1 |
| Laguno, M; Mallolas, J | 1 |
| Arizcorreta, A; Gutierrez-Valencia, A; Jimenez, L; Lopez-Cortes, LF; Ruiz-Valderas, R; Terrón, A; Valera-Bestard, B; Viciana, P | 1 |
| Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Salmon-Céron, D | 1 |
| Bruno, R; De Luca, A; García-Samaniego, J; González, M; Losada, E; Mariño, A; Martín-Carbonero, L; Núñez, M; Puoti, M; Quinzan, G; Soriano, V | 1 |
| Bassetti, M; Beltrame, A; Dentone, C; Di Biagio, A; Lindstrom, V; Mazzarello, G; Ratto, S; Righi, E; Viscoli, C | 1 |
| Chatelut, E; Dubois, M; Izopet, J; Lafont, T; Legrand-Abravanel, F; Nicot, F; Pasquier, C; Sauné, K | 1 |
| Barreiro, P; García-Gascó, P; Labarga, P; Maida, I; Martín-Carbonero, L; Morello, J; Rodriguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Lapointe, N; Lemay, M; Martin, SR; Quesnel-Vallières, M; Soudeyns, H | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Goderel, I; Larrat, S; Lunel-Fabiani, F; Martha, B; Morand, P; Payan, C; Perronne, C; Piroth, L; Pol, S | 1 |
| de Felipe, B; Gutiérrez, A; Leal, M; López-Cortés, L; Molina-Pinelo, S; Soriano-Sarabia, N; Vallejo, A | 1 |
| Capodiferro, S; Giuliani, M; Lajolo, C; Sartorio, A; Scivetti, M; Tumbarello, M | 1 |
| Arduino, R; Barnett, B; Bolcic, F; Bull, L; Martinez, L; Quarleri, J; Reynoso, R; Salomon, H | 1 |
| Deutch, M; Dourakis, S; Ioannidou, P; Karafoulidou, A; Katsarou, O; Kouraba, A; Nomikou, E; Terpos, E; Theodosiades, G; Tsevrenis, B | 1 |
| Castro, G; Figueiredo, JF; Martinelli, Ade L; Ramalho, LN; Zucoloto, S | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Barreiro, P; González, M; Gonzalez-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Arnsten, JH; Gourevitch, MN; Harris, KA; Kaswan, D; Litwin, AH; Nahvi, S; Soloway, IJ; Tenore, PL; Zamor, PJ | 1 |
| Bonet, L; Cifuentes, C; Gatell, JM; Laguno, M; Laufer, N; Mallolas, J; Murillas, J; Perez, I; Veloso, S; Vidal, F | 1 |
| Hoffman, CJ; Ray, SC | 1 |
| Gault, E; Girard, PM; Gozlan, J; Lacombe, K; Raguin, G | 1 |
| Adams, O; Emmelkamp, J; Häussinger, D; Kupfer, B; Oette, M; Rockstroh, J; Sagir, A; Vogel, M | 1 |
| Liebman, HA | 1 |
| Bassa, A; Blanco, JL; Bonet, L; Calvo, M; Cifuentes, C; Gatell, JM; Laguno, M; Larrousse, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Milinkovic, A; Murillas, J; Payeras, A; Pérez, I; Sánchez-Tapias, JM; Tural, C; Veloso, S; Vidal, F; Villalonga, C | 1 |
| Bhatti, L; Dieterich, DT; Edlin, BR; Fishbein, DA; Goetz, MB; Wagner, GJ; Weiss, JJ; Yu, K | 1 |
| Pozza, R | 1 |
| Lu, Y; Robinson, M; Zhang, FJ | 1 |
| Baker, D; Dore, GJ; Haber, P; Hellard, M; Kaldor, J; Lloyd, A; Marks, P; Matthews, GV; McCaughan, G; Rawlinson, W; Sasadeusz, J; White, P; Yeung, B | 1 |
| Macías, J; Mira, JA; Neukam, K; Pineda, JA | 1 |
| Aberle, JH; Gangl, A; Holzmann, H; Kohrgruber, N; Kundi, M; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Cirera, I; Clotet, B; Coll, S; Galeras, JA; García-Retortillo, M; Giménez, D; Márquez, C; Planas, R; Rey-Joly, C; Salas, A; Sirera, G; Solà, R; Tor, J; Tural, C; Videla, S | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Alberti, A | 1 |
| Arribas, JR; Fraile, JM; González, JJ; Montes, ML | 1 |
| de los Santos-Gil, I; del Valle, J; Fernández-Fuertes, E; González-Serrano, M; Macías, J; Merchante, N; Merino, D; Mira, JA; Moro, A; Pineda, JA; Ruiz-Morales, J; Sanz-Sanz, J | 1 |
| Cammà, C; Petta, S | 1 |
| Carbonell, J; Crespo, M; Curran, A; Esteban, JI; Esteban, R; Falco, V; Imaz, A; Jardi, R; Ocaña, I; Pahissa, A; Ribera, E; Rodríguez-Frias, F; Van den Eynde, E; Villar del Saz, S | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Foltzer, A; Gerard, L; Lapidus, N; Perronne, C; Pol, S; Rosenthal, E | 1 |
| Bellón, JM; Berenguer, J; Esteban, H; González-García, J; Hernando, A; López-Aldeguer, J; Mallolas, J; Miralles, P; Montes, ML; Ortega, E; Quereda, C; Santos, I; Sanz, J; Tural, C; Von-Wichmann, MA | 1 |
| Pol, S | 4 |
| Bani-Sadr, F | 1 |
| Piroth, L | 1 |
| Marks, K; Talal, AH; Wan, DW; Yantiss, RK | 1 |
| Bräu, N; Fishbein, D; Stivala, A; Swan, T; Weiss, JJ | 1 |
| Bédossa, P; Cacoub, P; Carrat, F; Halfon, P; Lambert, J; Pénaranda, G; Perronne, C; Pol, S | 1 |
| Arends, JE; Baak, LC; Boland, GJ; Hoepelman, AI; Simons, CP; Stuart, JC; van Baarle, D; van der Ende, ME; van Erpecum, KJ | 1 |
| Cheng, DX; Chu, YL; Liu, EQ; Xue, X; Zhao, SH | 1 |
| Gluud, LL; Iorio, A; Marchesini, E | 1 |
| Alvarez-Pellicer, J; Bellón, JM; Berenguer, J; González-García, J; López-Aldeguer, J; Mallolas, J; Martín, PM; Quereda, C; Sanz, J; Tural, C; Von-Wichmann, MA | 1 |
| Andreoni, M; Angeli, E; Carbone, R; Cargnel, A; Giorgi, R; Gubertini, G; Mainini, A; Orani, A; Rizzardini, G; Schiavini, M; Uberti-Foppa, C | 1 |
| Berenguer, J; Girón, JA; González-Serrano, M; Iribarren, JA; Japón, MA; López-Cortés, LF; Macías, J; Mira, JA; Miralles, P; Moreno, A; Ortega, E; Pineda, JA; Rivero, A | 1 |
| Adams-Huet, B; Attar, N; Carney, DS; Gale, M; Jain, MK; Lee, WM; Neumann, AU; Reeck, A; Shelton, J; Yuan, HJ; Zhang, S | 1 |
| Alaeus, A; Blom, KG; Falconer, K; Gonzalez, VD; Laursen, AL; Mørn, B; Reichard, O; Sandberg, JK; Weis, N | 1 |
| Nelson, M; Page, E; Rockstroh, JK; Vogel, M | 1 |
| Cadranel, JF; Lahmek, P; Morin, T; Pariente, A; Rabaud, C; Silvain, C | 1 |
| Arponen, S; Collado, A; Delgado, M; Gil, Ide L; González-Serrano, M; Gutiérrez-Valencia, A; López-Ruz, MA; Macías, J; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortosa, M | 1 |
| Berenguer, J; Catalán, P; Cosín, J; González-Nicolás, J; López, JC; Lorente, R; Micheloud, D; Miralles, P; Muñoz-Fernández, M; Resino, S | 1 |
| Dore, GJ; French, R; Grebely, J; Haber, PS; Hellard, M; Kaldor, JM; Lloyd, AR; Marks, P; Matthews, GV; McCaughan, G; Petoumenos, K; Rawlinson, W; van Beek, I; White, P; Yeung, B | 1 |
| Adorni, F; Antinori, S; Caramma, I; Cesari, M; Galli, M; Milazzo, L | 1 |
| Avidan, NU; Buti, M; Fauci, AS; Ferenci, P; Goldstein, D; Kottilil, S; Masur, H; McLaughlin, M; Polis, MA; Rozenberg, L | 1 |
| Aghemo, A; Colombo, M; Coppola, A; Mancuso, ME; Mannucci, PM; Puoti, M; Rumi, MG; Santagostino, E | 1 |
| Bédossa, P; Cacoub, P; Carrat, F; Halfon, P; Lambert, J; Pénaranda, G; Pol, S | 1 |
| Barreiro, P; García-Samaniego, J; Jiménez-Nácher, I; Labarga, P; Madejón, A; Martín-Carbonero, L; Medrano, J; Resino, S; Rodríguez, V; Soriano, V; Tuma, P; Vispo, E | 1 |
| Breilh, D; Chêne, G; Djabarouti, S; Dupon, M; Fleury, H; Le Bail, B; Neau, D; Ragnaud, JM; Saux, MC; Thiébaut, R; Trimoulet, P | 1 |
| Chen, G; Dewar, RL; Ferenci, P; Haagmans, BL; Kottilil, S; Levy-Drummer, RS; Masur, H; McLaughlin, M; Neumann, AU; Polis, MA; Rozenberg, L; Silva, M; Viola, MS | 1 |
| Alaeus, A; Falconer, K; Reichard, O; Sandberg, JK | 1 |
| Dionne-Odom, J; Grakoui, A; Osborn, MK; Radziewicz, H; Workowski, K | 1 |
| Cingolani, A; De Luca, A; Donato, C; Pinnetti, C | 1 |
| Berenguer, J; Catalán, P; Cosín, J; López, JC; Miralles, P; Resino, S; Vargas, A | 1 |
| Alajos, P; Béla, H; Ferenc, S; Gábor, H; István, T; Judit, G; László, T; Mihály, M | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Maida, I; Martin-Carbonero, L; Soriano, V; Sotgiu, G; Vispo, E | 1 |
| Awad, T; Gluud, LL; Iorio, A; Marchesini, E | 1 |
| Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Madejón, A; Medrano, J; Morello, J; Rodríguez-Novoa, S; Soriano, V | 1 |
| Barreiro, P; Labarga, P; Martín-Carbonero, L; Medrano, J; Morello, J; Pinilla, J; Rodríguez-Novoa, S; Soriano, V; Tuma, P; Vispo, E | 1 |
| Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D | 1 |
| Antinori, S; Caramma, I; Cesari, M; Galli, M; Mazzali, C; Milazzo, L; Olivetti, M | 1 |
| Rockstroh, JK; Vogel, M | 2 |
| Amorosa, VK; Bruno, C; Dorey-Stein, Z; Ferrara, T; Hoffman-Terry, M; Kostman, JR; Lo Re, V; Mounzer, K; Slim, J | 1 |
| Begovac, J; Romih, V | 1 |
| Jmelnitzky, AC; Jorge, O; Manero, E | 1 |
| Nilsson, J; Weiland, O | 1 |
| Cañete, N; Crespo, M; Jou, A; Mira, JA; Pahissa, A; Pineda, JA; Podzamczer, D; Solà, R; Tiraboschi, JM; Tural, C; Van den Eynde, E | 1 |
| Bruix, J; Forns, X | 1 |
| Aguirrebengoa, K; Barreiro, P; Guardiola, JM; Labarga, P; Miralles, C; Miralles, P; Morello, J; Portu, J; Rodriguez-Novoa, S; Rubio, R; Soriano, V; Vispo, E | 1 |
| Azwa, A; Bhagani, S; Dominguez, S; Guiguet, M; Katlama, C; Nelson, M; Page, E; Rockstroh, JK; Valantin, MA; Vogel, M | 1 |
| Benito, JM; Goldstein, D; McHutchison, J; Medrano, J; Naggie, S; Rallón, NI; Restrepo, C; Shianna, KV; Soriano, V; Thompson, A; Vispo, E | 1 |
| Bárcena, R; Blesa, C; Casado, JL; Fortún, J; Mateos, ML; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Ahlenstiel, G; Baumgarten, A; Bickel, M; Buggisch, P; Fenske, S; Gölz, J; Hintsche, B; John, C; Khaykin, P; Klinker, H; Lutz, T; Mayr, C; Rockstroh, JK; Schürmann, D; Staszewski, S; Stephan, C; Trein, A; Vogel, M | 1 |
| Barreiro, P; Jiménez-Nacher, I; Labarga, P; Madejón, A; Martín-Carbonero, L; Medrano, J; Resino, S; Rodriguez-Novoa, S; Soriano, V; Tuma, P; Vispo, E | 1 |
| Breitenecker, F; Gangl, A; Kosi, L; Maresch, J; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Wrba, F | 1 |
| Berenguer, J; Catalán, P; Cosín, J; López, JC; Miralles, P; Resino, S; Ryan, P; Vargas, A | 1 |
| Bernardini, C; Di Biagio, A; Mikulska, M; Nicco, E; Rosso, R; Viscoli, C | 1 |
| Autran, B; Blanco, J; Bofill, M; Clotet, B; Garcia, E; Jou, A; Massanella, M; Papagno, L; Tural, C | 1 |
| Affonso de Araujo, ES; Barone, AA; Cotler, SJ; Dahari, H; Haagmans, BL; Layden, TJ; Neumann, AU | 1 |
| Berenguer, J; Catalán, P; Cosín, J; Gutiérrez, I; López, JC; Miralles, P; Moreno, S; Ramírez, M; Resino, S; Ryan, P | 1 |
| Andersen, J; Bhattacharya, D; Carrat, F; Chung, RT; Currier, JS; Peters, MG; Torriani, F; Umbleja, T | 1 |
| Mendes-Corrêa, M; Núñez, M | 1 |
| Bernasconi, E; Borovicka, J; Cavassini, M; Cerny, A; Chave, JP; Chuard, C; Dufour, F; Dutoit, V; Genné, D; Gonvers, JJ; Heim, MH; Malinverni, R; Monnat, M; Müllhaupt, B; Negro, F; Oneta, C; Troilliet, N | 1 |
| Camacho, A; del Valle, J; Macías, J; Mata, R; Merchante, N; Mira, JA; Neukam, K; Pérez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J | 1 |
| Chary, A; Holodniy, M; Kottilil, S; Murphy, AA; Polis, MA; Winters, MA | 1 |
| Burbelo, PD; Ching, KH; Iadarola, MJ; Issa, AT; Kottilil, S; Kovacs, JA; Masur, H; Murphy, AA; Polis, MA; Schlaak, JF | 1 |
| Ceccherini-Silberstein, F; Cento, V; Di Masi, F; Manzoli, L; Mazzotta, E; Mercurio, F; Parruti, G; Perno, CF; Pieri, A; Polilli, E; Sozio, F; Tontodonati, M | 1 |
| Beinhardt, S; Ferenci, P; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Staettermayer, AF | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Chavanet, P; Duong, M; Duvillard, L; Halfon, P; Petit, JM; Piroth, L | 1 |
| Araújo, ES; Barone, AA; Cotler, SJ; Dahari, H; de Melo, ES; de Paula Cavalheiro, N; Layden, TJ; Melo, CE; Neumann, AU | 1 |
| Badley, AD; Cummins, NW; Klein, MB; Rider, DN; Rizza, SA; Saeed, S | 1 |
| Camacho, A; Caruz, A; de la Torre, J; Macías, J; Martínez, A; Mira, JA; Neukam, K; Palomares, JC; Pineda, JA; Rivero, A; Roldán, C; Salas, I | 1 |
| Barreiro, P; Cuenca, L; Jiménez-Nácher, I; Labarga, P; Madejón, A; Medrano, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Barreiro, P; González-Lahoz, J; Labarga, P; Martín-Carbonero, L; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Alston, B; Andersen, JW; Butt, AA; Chung, RT; Goodman, ZD; Koziel, MJ; Peters, MG; Sherman, KE; Sulkowski, M; Umbleja, T | 1 |
| Barreiro, P; Benito, JM; Calvino, A; Caruz, A; Macías, J; McHutchison, J; Medrano, J; Naggie, S; Neukam, K; Pineda, JA; Rallón, N; Resino, S; Rivero, A; Sánchez-Piedra, C; Soriano, V; Vispo, E | 1 |
| Branch, AD; Bräu, N; Dieterich, DT; Factor, SH; Fiel, MI; Rodriguez-Torres, M; Slim, J; Sterling, RK; Sulkowski, MS; Talal, AH; Vachon, ML | 1 |
| Casteelen, G; Coutinho, RA; Jansen, PL; Krol, A; Lambers, FA; Lindenburg, CE; Prins, M; Schinkel, J; Urbanus, AT; van den Berg, CH; van Santen, G; Weegink, CJ | 1 |
| Aparicio, E; Clotet, B; Franco, S; Martínez, MA; Parera, M; Pérez-Alvarez, N; Tural, C | 1 |
| Abbate, I; Agrati, C; Capobianchi, MR; D'Offizi, G; Martini, F; Rozera, G; Sacchi, A; Vlassi, C | 1 |
| Barone, AA; Cotler, SJ; Dahari, H; de Araujo, ES; Layden, TJ; Melo, CE; Neumann, AU | 1 |
| Burger, DM; Dofferhoff, TS; Drenth, JP; Huntjens-Fleuren, HW; Koopmans, PP; Richter, C; Slavenburg, S; Verwey-Van Wissen, CP | 1 |
| Kovacs, A; Operskalski, EA | 1 |
| Amador, C; Benito, C; Ena, J; Pasquau, F; Ruiz-de-Apodaca, RF | 1 |
| Alric, L; Barange, K; Barel, P; Castan, B; Chatelut, E; Combis, JM; Desmorat, H; Dramard, JM; Garipuy, D; Guerin, B; Imbert, Y; Izopet, J; Métivier, S; Meurisse, JJ; Morin, T; Nicot, F; Payen, JL; Peron, JM; Renou, C; Sauné, K; Sire, S; Thebault, S | 1 |
| Berenguer, J; Carrero-Gras, A; Catalán, P; Cosín, J; García-Álvarez, M; Guzmán-Fulgencio, M; López, JC; Micheloud, D; Miralles, P; Resino, S | 1 |
| Blanco, JL; Calvo, M; González, A; Laguno, M; Larrousse, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A | 1 |
| Cacoub, P; Carrat, F; Geri, G; Halfon, P; Piroth, L; Pol, S; Poynard, T; Souberbielle, JC; Terrier, B | 1 |
| Bolcic, F; Cahn, P; Laufer, N; Martinez, A; Pérez, H; Quarleri, J; Reynoso, R; Rolón, MJ; Salomón, H | 1 |
| Aldamiz-Echevarría, T; Berenguer, J; Cosín, J; de Castro, IF; Guzmán-Fulgencio, M; López, JC; Lorente, R; Micheloud, D; Miralles, P; Muñoz-Fernández, MÁ; Resino, S | 1 |
| Camacho, A; Macías, J; Merchante, N; Mira, JA; Neukam, K; Pérez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J | 1 |
| Laguno Centeno, M; Mallolas Masferrer, J; Martínez-Rebollar, M | 1 |
| Berenguer, J; C López, J; Catalán, P; Cosín, J; Fernández de Castro, I; García-Álvarez, M; Guzmán-Fulgencio, M; Micheloud, D; Miralles, P; Resino, S | 1 |
| Andrés, C; Aparicio, E; Clotet, B; Franco, S; Martínez, MA; Parera, M; Tural, C | 1 |
| Baxter, L; Hartwell, D; Jones, J; Shepherd, J | 1 |
| Benito, JM; Goldstein, D; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E | 1 |
| Boesecke, C; Rockstroh, JK | 2 |
| Andersen, JW; Butt, AA; Chung, RT; Sherman, KE; Umbleja, T | 2 |
| Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Mira, JA; Neukam, K; Pineda, JA; Pinilla, J; Rallón, N; Rivero, A; Rodriguez-Novoa, S; Soriano, V; Vispo, E | 1 |
| Camacho, A; Caruz, A; Di Lello, FA; Gómez-Mateos, J; Macías, J; Mesa, P; Neukam, K; Pineda, JA; Rivero, A; Rivero-juárez, A | 1 |
| Antinori, S; Bestetti, G; Foschi, A; Galli, M; Longhi, E; Mazzali, C; Milazzo, L; Parravicini, C; Vago, T; Viola, A | 1 |
| Chung, TL; Haagmans, BL; Herrmann, E; Kottilil, S; Lempicki, RA; Murphy, AA; Osinusi, AO; Polis, MA; Sachau, W; Wood, BJ; Wu, L; Yang, J | 1 |
| Heil, PM; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Escolano, C; Gutiérrez, F; López, N; Masiá, M; Robledano, C | 1 |
| Arends, JE; van den Berk, GE | 1 |
| Da Silva, A; de Juan, J; del Pozo, E; Faraco, I; Marco, A; Saiz de la Hoya, P; Veiras, FM; Yllobre, C | 1 |
| Carrieri, MP; Dabis, F; Fugon, L; Lacombe, K; Roux, P; Salmon-Céron, D; Sogni, P; Spire, B; Winnock, M | 1 |
| Moreno, V; Valencia, ME | 1 |
| Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M | 1 |
| Aberg, JA; Aboulafia, D; Bonilla, H; Dimova, R; Doonquah, L; Dove, L; Galpin, J; Glesby, MJ; Hassanein, T; Jacobson, IM; Johnston, B; Liu, RC; Pearce, D; Rodriguez, J; Talal, AH; Zeremski, M | 1 |
| Carrieri, MP; Cohen, J; Salmon-Ceron, D; Winnock, M | 1 |
| Alvarez, NP; Clotet, B; González, J; Laguno, M; Moltó, J; Ornelas, A; Paredes, R; Sánchez, M; Solà, R; Téllez, MJ; Tural, C; von Wichmann, MÁ; Zamora, AM | 1 |
| Bruno, R; Fagiuoli, S; Sacchi, P | 1 |
| Chary, A; Holodniy, M | 1 |
| Macías, J; Pineda, JA; Soriano, V; Vispo, E | 1 |
| Kohli, A; Kottilil, S; Masur, H; Migueles, S; Naggie, S; Polis, MA; Shivakumar, B; Sidique, N; Subramanian, GM | 1 |
| Baily, G; Buckland, M; Dorward, J; Garrett, N; Orkin, C; Scott, D | 1 |
| Eslam, M; López-Cortés, LF; Romero-Gomez, M | 1 |
| Razonable, RR | 1 |
| Alvarez-Pellicer, J; Arponen, S; Barquilla, E; Bellón, JM; Berenguer, J; Crespo, M; De Miguel, J; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Mallolas, J; Miralles, P; Quereda, C; Tellez, MJ; von Wichmann, MA | 1 |
| Bendall, R; Dalton, HR; Ijaz, S; Keane, FE; Mathew, J | 1 |
| Camacho Espejo, A; Caruz, A; García-Lázaro, M; Mesa, P; Mira, JA; Neukam, K; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J | 1 |
| Bergin, C; Dillon, A; Farrell, G; Jackson, A; Kieran, J; Mulcahy, F; Norris, S | 1 |
| Boesecke, C; Vogel, M | 1 |
| Bhagani, S | 1 |
| Chung, RT; Dayyeh, BK; de Bakker, PI; Gupta, N; Sherman, KE | 1 |
| Arends, JE; Fransen, JH; Hoepelman, AI; Mudrikova, T; Schellens, IM; Spijkers, SN; Sprenger, HG; Stek, CJ; van Assen, S; van Baarle, D; Wensing, AM | 1 |
| Aguirrebengoa, K; Barreiro, P; Benito, JM; Castro, MÁ; Labarga, P; Miralles, C; Miralles, P; Morello, J; Ocampo, A; Pineda, JA; Portu, J; Rallón, NI; Rodríguez-Nóvoa, S; Soriano, V; Tellez, MJ; Vispo, E | 1 |
| Aberle, J; Ferenci, P; Holzmann, H; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Côrtes, R; Diaz, RS; Ferreira, PR; Reis, A; Santos, C; Silva, MH; Tenore, Sde B; Vilhena, C | 1 |
| Bergin, C; Hennessy, M; Hopkins, S; Kennedy, A; Mulcahy, F; Spiers, JP | 1 |
| Di Martino, V; Kantelip, JP; Monnet, E; Montange, D; Muret, P; Piedoux, S; Piroth, L; Royer, B; Thevenot, T | 1 |
| Benito, JM; Clark, PJ; Goldstein, DB; McHutchison, JG; Morello, J; Naggie, S; Rallon, NI; Rodriguez-Novoa, S; Shianna, KV; Soriano, V; Thompson, AJ; Vispo, E | 1 |
| Benito, JM; Camacho, A; Caruz, A; Gómez-Mateos, J; López-Cortés, LF; Macías, J; Nattermann, J; Neukam, K; Pineda, JA; Rallón, N; Rivero, A; Rockstroh, JK; Soriano, V; Torres-Cornejo, A | 1 |
| González-Escribano, MF; Jimenez-Jimenez, L; López-Cortés, LF; Marquez-Solero, M; Mata, R; Pineda, JA; Rivero, A; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Bolcic, F; Laufer, N; Moretti, F; Quarleri, J; Sede, M; Vazquez, M; Westergaard, G | 1 |
| Berenguer, J; Cosín, J; Fernández-Rodríguez, A; Guzmán-Fulgencio, M; Jiménez, JL; López, JC; Micheloud, D; Miralles, P; Muñoz-Fernández, MÁ; Resino, S | 1 |
| Benito, JM; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E | 1 |
| Balzarini, J; Derudas, M; Grivel, JC; Introini, A; Lisco, A; Margolis, L; McGuigan, C; Merbah, M; Munawwar, A; Schinazi, RF; Vanpouille, C | 1 |
| Jablonowska, E; Nocun, M; Wojcik, K | 1 |
| Aparicio, E; Clotet, B; de Castellarnau, M; Franco, S; Martínez, MA; Parera, M; Tural, C | 1 |
| Clark, PJ; Herrmann, E; Katsounas, A; Kottilil, S; Lempicki, R; Masur, H; McHutchison, JG; Muir, AJ; Naggie, S; Osinusi, A; Patel, K; Polis, MA; Schlaak, JF; Shivakumar, B; Thompson, AJ; Trippler, M | 1 |
| Aoun, O; Bricaire, F; Mellon, G; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA | 1 |
| Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Neukam, K; Pineda, JA; Rallón, NI; Restrepo, C; Rivero, A; Soriano, V; Vispo, E | 1 |
| Bai, F; Bellistrì, GM; Borghi, F; Carosi, G; Gatti, F; Marchetti, G; Monforte, Ad; Nasta, P; Puoti, M; Tincati, C | 1 |
| Camacho, A; Caruz, A; Di Lello, FA; Gonzalez, R; Mesa, P; Neukam, K; Peña, J; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Torre-Cisneros, J | 1 |
| Bouvier-Alias, M; Cassard, B; Dominguez, S; Ghosn, J; Katlama, C; Lascaux, AS; Lévy, Y; Melica, G; Peytavin, G; Poizot-Martin, I; Solas, C | 1 |
| Loulergue, P; Mir, O; Sogni, P | 1 |
| Aichelburg, MC; Breitenecker, F; Ferenci, P; Heil, PM; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scherzer, TM; Schuster, C | 1 |
| Takeda, T | 1 |
| Baiget, M; Del Mar Gutierrez, M; Domingo, P; Fontanet, A; Guardiola, JM; Lamarca, K; Martin, J; Mateo, MG; Muñoz, J; Pacho, C; Salazar, J; Torres, F; Vidal, F | 1 |
| Freedberg, KA; Kim, AY; Linas, BP; Schackman, BR; Wong, AY | 1 |
| Burnett, D; Cornett, DD; Lindstrom, MJ; Lucey, MR; Rice, JP; Sawyer, J; Striker, R; Tsotsis, H; Voermans, P | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Krastinova, E; Perronne, C; Piroth, L; Pol, S; Quertainmont, Y; Rosenthal, E | 1 |
| Fishbein, D; Funk, E; Hu, Z; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, M; Poonia, S; Schlaak, J; Trippler, M | 1 |
| Barros, C; Bellón, JM; Berenguer, J; Esteban, H; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jou, A; Jusdado, JJ; López-Aldeguer, J; Mallolas, J; Miralles, P; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rodríguez, E; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Van Den Eynde, E; Von Wichmann, MA | 1 |
| Amin, J; Dore, GJ; George, J; Gidding, HF; Haber, PA; Law, MG; Macdonald, GA; Ostapowicz, G; Sasadeusz, JJ; Weltman, M | 1 |
| Bolcic, F; Cassino, L; Laufer, N; Quarleri, J; Reynoso, R; Torres, C | 1 |
| de Los Santos-Gil, I; del Mar Viloria, M; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Bailly, F; Zoulim, F | 1 |
| Barreiro, P; Benito, JM; Labarga, P; Rallon, NI; Soriano, V; Vispo, E | 1 |
| Katsounas, A; Kottilil, S; Lempicki, RA; Masur, H; Murphy, AA; Osinusi, A; Polis, M; Rasimas, J; Raza, H; Rosenstein, D; Yang, J | 1 |
| Anthony, DD; Blanton, RE; Conry, SJ; Falck-Ytter, Y; Landay, AL; Lederman, MM; Medvik, K; Rodriguez, B; Sandberg, JK; Sandhya Rani, MR | 1 |
| Fujisaki, S; Goto, H; Hibino, Y; Hirashima, N; Iwase, H; Kamiya, A; Ryuge, N; Saito, M; Shimada, M; Sugiura, W; Tamaki, D; Tsuzuki, T; Yokoi, M; Yokomaku, Y | 1 |
| Aguirrebengoa, K; Asensi, V; Barreiro, P; Castro, A; da Silva, A; Echeverría, S; Guardiola, JM; Hernández-Quero, J; Labarga, P; Mariño, A; Miralles, P; Morano, L; Pineda, JA; Portu, J; Ríos, MJ; Rubio, R; Soriano, V; Téllez, MJ; Terrón, A; Vispo, E | 1 |
| Amorosa, VK; Gross, R; Kaplan, DE; Lo Re, V; Localio, AR; Teal, V | 1 |
| Jabłonowska, E; Koślińska-Berkan, E; Omulecka, A; Piekarska, A; Szymańska, B; Wójcik, K | 1 |
| Chary, A; Holodniy, M; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, MA; Winters, MA | 1 |
| Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Schmied, B; Sieghart, W; Trauner, M | 1 |
| de los Santos-Gil, I; García-Rey, S; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Cachay, ER | 1 |
| Andersen, JW; Butt, AA; Chung, RT; Hua, L; Kemmer, N; Sherman, KE | 1 |
| Asensi, V; Cartón, JA; Collazos, J; de la Fuente, B | 1 |
| Camacho, A; Caruz, A; Macias, J; Mira, JA; Neukam, K; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Torre-Cisneros, J | 1 |
| Bárcena, R; Casado, JL; Del Campo, S; Dronda, F; Mateos, ML; Montes, M; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Arnedo, M; Auguet, T; Cifuentes, C; Gallart, L; Gatell, JM; Hernandez, P; Laguno, M; López-Dupla, M; Mallolas, J; Murillas, J; Payeras, A; Richart, C; Sampériz, G; Veloso, S; Vidal, F | 1 |
| Camacho, A; Caruz, A; Gutierrez-Valencia, A; Lopez-Cortes, LF; Marquez-Solero, M; Pineda, JA; Rivero, A; Rivero-Juárez, A; Ruiz-Valderas, R; Torre-Cisneros, J; Torres-Cornejo, A | 1 |
| Driver, TH; Saxena, V; Terrault, N | 1 |
| Kwo, PY | 1 |
| Benguria, A; Benito, JM; Fiorante, S; Garcia, MI; Lopez-Fernandez, LA; Rallon, NI; Soriano, V | 1 |
| Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Mandorfer, M; Obermayer-Pietsch, B; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Trauner, M | 1 |
| Almeida, C; Benito, JM; Camacho, A; Caruz, A; Di Lello, FA; Herrero, R; Macías, J; Neukam, K; Pineda, JA; Rallón, NI; Rivero, A; Rivero-Juárez, A; Soriano, V | 1 |
| Egle, A; Greil, R; Grundbichler, M; Melchardt, T; Strasser, M; Taylor, N | 1 |
| Dimova, RB; Jacobson, IM; Makeyeva, J; Rennert, H; Sipley, JD; Talal, AH; Zeremski, M | 1 |
| Baruch, Y; Hassoun, G; Kramskay, R; Lorber, M; Maor, C; Pollack, S; Shahar, E; Veitsman, E | 1 |
| Sönnerborg, A; Stenkvist, J; Weiland, O | 1 |
| Alvarez-Pellicer, J; Barquilla, E; Barros, C; Bellón, JM; Berenguer, J; Carrero, A; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jusdado, JJ; López-Aldeguer, J; Mallolas, J; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Tural, C; Van Den Eynde, E; Von Wichmann, MA | 1 |
| Cano, Y; Guyader, D; Poinsignon, Y; Saout, L | 1 |
| Bruno, R; Carosi, G; Filice, G; Puoti, M; Sacchi, P | 1 |
| Bernard, N; Dupon, M; Fleury, H; Galperine, T; Houghton, M; Lacut, JY; Lafon, ME; Le Bail, B; Legrand, E; Moreau, JF; Neau, D; Pitard, V; Ragnaud, JM; Schvoerer, E; Trimoulet, P | 1 |
| Bruno, R; Filice, G; Puoti, M; Sacchi, P; Soriano, V | 1 |
| Craven, DE; Nunes, DP | 1 |
| Maier, I; Wu, GY | 1 |
| Gervais, A | 1 |
| Pawlotsky, JM | 2 |
| Perronne, C | 2 |
| Dhumeaux, D; Lerebours, E; Marcellin, P | 1 |
| Montes Ramírez, ML; Rodríguez Zapata, M | 1 |
| Dupke, S; Gölz, J; Klausen, G; Lichterfeld, M; Mauss, S; Mudar, M; Nischalke, HD; Notheis, G; Rockstroh, JK; Stein, L | 1 |
| Blanco, F; Garcia-Benayas, T; Soriano, V | 1 |
| Diamond, C; Lee, JH | 1 |
| Craven, DE; Fleming, CA; Nunes, D; Thornton, D; Tumilty, S | 1 |
| Bray, M; Wright, ME | 1 |
| Curran, MP; Keating, GM | 1 |
| Ivanikov, IO; Pomova, NI; Siutkin, VE | 1 |
| Brenner, B; Campeol, N; Klein, MB; Lalonde, RG; Wainberg, MA | 1 |
| Arribas, JR; Barreiro, P; Castro, A; García-Samaniego, J; González, J; Jiménez-Nácher, I; Martín-Carbonero, L; Núñez, M; Pedreira, J; Pérez-Olmeda, M; Romero, M; Soriano, V | 1 |
| Dupon, M; Fleury, H; Galpérine, T; Lafon, ME; Legrand, E; Moreau, JF; Neau, D; Neau-Cransac, M; Pitard, V; Ragnaud, JM | 1 |
| Juárez Navarro, JA | 1 |
| Benech, H; Bonnet, E; Bouvier-Alias, M; Chêne, G; Goujard, C; Lassalle, R; Morlat, P; Payan, C; Pérusat, S; Pruvost, A; Salmon-Céron, D; Sogni, P; Tréluyer, JM; Zoulim, F | 1 |
| Monarch, A | 1 |
| Allen, S; Jacobs, G; Mitty, J; Schwartzapfel, B; Taylor, LE | 1 |
| Boeri, E; De Bona, A; Galli, L; Gallotta, G; Lazzarin, A; Morsica, G; Uberti-Foppa, C | 1 |
| Bioulac-Sage, P; Chêne, G; Dupon, M; Lacoste, D; Lafon, ME; Le Bail, B; Neau, D; Ragnaud, JM; Rullier, A; Trimoulet, P; Winnock, M | 1 |
| Bica, I; McGovern, B | 1 |
| Butt, AA | 1 |
| Gerber, JG; Glesby, MJ | 1 |
| Dixit, NM; Golia, P; Perelson, AS; Powers, KA; Ribeiro, RM; Talal, AH | 1 |
| Dwyer, JT; Paul, SM | 1 |
| Clauson, M; Gilbert, TL; Pacheco, DM; Perelson, AS; Ribeiro, RM; Schrenk, UM; Torriani, FJ | 1 |
| Bruno, R; Filice, G; Sacchi, P | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| Asensi, V; Blanch, J; García-Samaniego, J; Guardiola, J; Jiménez-Nácher, I; Morales, D; Núñez, M; Ochoa, A; Pérez-Olmeda, M; Romero, M; Sánchez-Montero, F; Santin, M; Soriano, V | 1 |
| Wilde, JT | 1 |
| Ball, L; Berggren, R; Dieterich, DT; Felizarta, F; Goodman, R; Khalili, M; Slim, J; Smith, C; Sulkowski, MS | 1 |
| Antela, A; Bárcena, R; Casado, JL; Dronda, F; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Navas, E; Perez-Elías, MJ; Quereda, C | 1 |
| Bonacini, M; Bräu, N; Frost, KR; Giffen, CA; Kostman, JR; Prokupek, D; Rodriguez-Torres, M; Smith, JJ | 1 |
| Cacoub, P; Cargnel, A; Dieterich, D; Hatzakis, A; Mauss, S; Puoti, M; Rockstroh, J; Soriano, V; Sulkowski, M | 1 |
| Antela, A; Bárcena, R; Casado, JL; Dronda, F; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Perez-Elías, MJ; Quereda, C | 1 |
| Acosta, L; Ballesteros, AL; Clotet, B; Franco, S; Fuster, D; Martínez, MA; Planas, R; Rey-Joly, C; Salas, A; Sirera, G; Tor, J; Tural, C | 1 |
| Benhamou, Y; Bochet, M; Mehri, D; Myers, RP; Poynard, T; Thibault, V | 1 |
| Alatrakchi, N; Autran, B; Benhamou, Y; Di Martino, V; Katlama, C; Poynard, T; Thibault, V | 1 |
| Bottieau, E; Callens, S; Colebunders, R; Michielsen, P | 1 |
| Boxwell, D; Fleischer, R; Sherman, KE | 1 |
| Balestreri, L; Canzonieri, V; Cinelli, R; Dal Maso, L; Di Gennaro, G; Fedele, P; Nasti, G; Tedeschi, R; Tirelli, U | 1 |
| Andreone, P; Bagaglio, S; Bruno, R; De Mitri, MS; Lazzarin, A; Morsica, G | 1 |
| Boyle, B | 1 |
| Adeyemi, OM; Attar, B; Cotler, SJ; Gallagher, M; Ghaoui, R; Jensen, D; Wolen, D | 1 |
| García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Ammassari, A; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Fantoni, M; Marasca, G; Tamburrini, E; Tumbarello, M | 1 |
| Kottilil, S; Kovacs, JA; Polis, MA | 1 |
| Reich, B | 1 |
| Barnes, E; De Lalla, F; Fabris, P; Giordani, MT; Grasso, A; Tositti, G | 1 |
| Carosi, G; De Pamphilis, J; Dieterich, DT; Duff, F; Gonzalez-García, J; Katlama, C; Lazzarin, A; Lissen, E; Montaner, J; Passe, S; Rockstroh, JK; Rodriguez-Torres, M; Sasadeusz, J; Schrenk, UM; Sette, H; Torriani, FJ | 1 |
| Alston, B; Andersen, J; Bhan, AK; Chung, RT; Colquhoun, D; Harb, G; Koziel, MJ; Liu, T; Nevin, T; Peters, MG; Robbins, GK; Sherman, KE; van der Horst, C; Volberding, P | 1 |
| Artioli, S; Carosi, G; Maggiolo, F; Mignani, E; Paraninfo, G; Pastore, G; Puoti, M; Quinzan, GP; Raise, E; Ravasio, L; Resta, F; Rollo, A; Santantonio, T; Suter, F; Verucchi, G; Zaltron, S; Zanini, B | 1 |
| Cupelli, L; DePamphilis, J; Dieterich, D; Duff, F; Larrey, D; Mauss, S; Passe, S; Solsky, J; Torriani, FJ; Valenti, W | 1 |
| Bargallo, X; Blanco, JL; de Lazzari, E; García-Criado, A; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miquel, R; Murillas, J; Sánchez-Tapias, JM | 1 |
| Campbell, C; Farel, C; Koratich, C; Kottilil, S; Masur, H; McLaughlin, M; Metcalf, JA; Polis, MA; Robinson, MR; Suzman, DL | 1 |
| Khalili, M; Proietti, N | 1 |
| Sterling, RK; Sulkowski, MS | 1 |
| Teruya, K | 2 |
| Mauss, S | 2 |
| Rókusz, L | 1 |
| Barreiro, P; Camino, N; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martin-Carbonero, L; Núñez, M; Romero, M; Soriano, V | 1 |
| Gonzalez, SA; Jacobson, IM | 1 |
| Anderson, JP; Daifuku, R; Loeb, LA | 1 |
| Kostman, JR; Lo Re, V | 1 |
| Chung, RT; Yachimski, P | 1 |
| Lunel, F; Payan, C; Pivert, A | 1 |
| Bagheri, H; Barange, K; Fouladi, A; Lapeyre-Mestre, M; Montastruc, JL; Payen, JL; Vinel, JP | 1 |
| Keating, GM; Plosker, GL | 1 |
| Rich, JD; Tashima, KT; Taylor, LE | 1 |
| Agarwal, K; Dieterich, DT; Kontorinis, N | 2 |
| Gholam, PM | 1 |
| Franchini, M | 2 |
| Beld, MG; den Hollander, JG; Ruys, TA; van der Ende, ME; van der Meer, JT | 1 |
| Fredrick, RT; Hassanein, TI | 1 |
| Baldelli, F; Canovari, B; Conte, ME; Di Candilo, F; Francisci, D; Sfara, C; Stagni, G; Valente, M | 1 |
| Bani-Sadr, F; Benzekri, A; Cacoub, P; Carrat, F; Degott, C; Goujard, C; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E; Salmon-Céron, D | 1 |
| Manns, MP; Wedemeyer, H | 1 |
| Arizcorreta, A; Brun, F; Fernández-Gutiérrez, C; García Juárez, R; Girón-González, JA; Guerrero, F; Pérez-Guzmán, E | 1 |
| Bernard, EJ | 1 |
| Biglia, A; Blanch, J; Blanco, JL; de Pablo, J; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Miró, JM; Murillas, J | 1 |
| Ballesteros, AL; Clotet, B; Côté, H; Fuster, D; Garrabou, G; López, S; Martínez, E; Miró, O; Planas, R; Rey-Joly, C; Salas, A; Tor, J; Tural, C; Videla, S | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Núñez, M; Soriano, V | 1 |
| Antela, A; Bárcena, R; Blázquez, J; del Campo, S; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, L; Moreno, S; Perez-Elías, MJ; Quereda, C; Sánchez, J | 1 |
| Moreno-Otero, R | 1 |
| Egger, M; Furrer, H; Rauch, A; Reichen, J | 1 |
| Carrat, F; Perronne, C | 1 |
| Chung, RT; Horn, PS; James Koziel, M; Peters, MG; Rouster, SD; Sherman, KE; Shire, NJ | 1 |
| Alston-Smith, B; Bassett, R; Brass, C; Fichtenbaum, C; Glesby, MJ; Jacobson, EL; Owens, S; Race, EM; Sherman, KE; Sulkowski, M | 1 |
| Blanco, JL; Forns, X; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J; Sánchez-Tapias, JM | 1 |
| Cacoub, P | 1 |
| Sax, PE | 1 |
| Camino, N; Sheldon, J; Soriano, V | 1 |
| Boffito, M; Di Perri, G; Samarasinghe, YP | 1 |
| Bräu, N | 2 |
| González-Lahoz, J; Soriano, V | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Romero, M; Sánchez-Conde, M; Soriano, V | 1 |
| Taylor, LE | 1 |
| den Hollander, JG; Rijnders, BJ; van der Ende, ME; van Doornum, GJ | 1 |
| Jabłonowska, E | 1 |
| Bernard, N; Beylot, J; Bonarek, M; Bonnet, F; Dramé, M; Lacoste, D; Lafon, ME; Morlat, P; Ramanampamonjy, R; Rambeloarisoa, J; Seydi, M; Trimoulet, P | 1 |
| Levin, J | 1 |
| Lumb, J | 1 |
| Angeli, E; Cargnel, A; Duca, P; Giorgi, R; Gubertini, G; Mainini, A; Schiavini, M | 1 |
| Biglia, A; Blanco, JL; de Lazzari, E; García, F; García, M; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J | 1 |
| Barylski, C; Bernstein, D; Hoffman-Terry, M; Khalili, M; Lentz, E | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Jiménez-Nácher, I; Martín-Carbonero, L; Núñez, M; Rendón, AL; Romero, M; Soriano, V | 1 |
| Alvarez, D; Bini, EJ; Bräu, N; Dejesus, E; Dieterich, DT; Leitz, GJ; Sulkowski, MS | 1 |
| Alvarez Delgado, A; Fuertes Martín, A; Pérez García, ML | 1 |
| Chun, S; Sherman, KE | 1 |
| Alric, L; Boulestin, A; Izopet, J; Legrand-Abravanel, F; Nicot, F; Sandres-Sauné, K; Vinel, JP | 1 |
| Buitelaar, M; de Baar, MP; de Mendoza, C; Gonzalez-Lahoz, J; Sánchez-Conde, M; Soriano, V; Timmermans, E | 1 |
| Bárcena, R; Blesa, C; Fortún, J; García, M; García-Garzón, S; Martín-Dávila, P; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Otón, E; Quereda, C | 1 |
| Ding, PP; He, Y; Huang, L; Li, H; Zhang, CY; Zheng, YH; Zhou, HY; Zou, W | 1 |
| Bani-Sadr, F; Bentata, M; Cacoub, P; Carrat, F; Goujard, C; Hor, R; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E; Salmon-Ceron, D | 1 |
| Barreiro, P; Garcia-Samaniego, J; Gonzalez-Lahoz, J; Maida, I; Nunez, M; Ramos, B; Soriano, V | 1 |
| Arazo, P; Barreiro, P; Berdún, MA; Camino, N; Echevarría, S; García-Samaniego, J; Losada, E; Martín-Carbonero, L; Miralles, C; Núnez, M; Ocampo, A; Ramos, B; Romero, M; Santos, I; Soriano, V | 1 |
| Tien, PC | 1 |
| Back, D; Borucki, MJ; Dieterich, D; Gries, JM; Hoggard, PG; Lissen, E; Rodriguez-Torres, M; Soriano, V; Sulkowski, M; Torriani, FJ; Wang, K | 1 |
| Carter, M | 1 |
| Cengiz, C; Dieterich, DT; Park, JS; Saraf, N | 1 |
| Ding, PP; Gong, GZ; He, Y; Huang, L; Li, H; Yang, X; Zhang, CY; Zheng, YH; Zhou, HY; Zhou, W | 1 |
| Garcia-Samaniego, J; Maida, I; Martin-Carbonero, L; Nuñez, M; Soriano, V | 1 |
| Tedaldi, EM | 1 |
| Sherman, KE; Shire, NJ | 1 |
| Amick, C; Andalkar, A; Bica, I; Bradley, M; Drewniak, S; Fiore, J; Galvin, S; Libone, G; McGovern, B; Molinaro-Gudas, V; Ramsey, J; Scheft, H; Taglienti, P; Wurcel, A | 1 |
| Goelz, J; Jessen, H; Klausen, G; Mauss, S; Mutz, A; Rockstroh, JK; Schmutz, G; Schranz, D; Schulz, C; Voigt, E; Weitner, L | 1 |
| Bani-Sadr, F; Bonarek, M; Cacoub, P; Carrat, F; Colin de Verdiere, N; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E | 1 |
| Clotet, B; Force, L; Fuster, D; Gómez, G; González García, J; Huertas, JA; Pedrol, E; Planas, R; Sirera, G; Solà, R; Tor, J; Tural, C; Videla, S; Vilaró, J | 1 |
| Pialoux, G | 1 |
| Gholam, PM; Rich, JD; Schwartzapfel, B; Taylor, LE | 1 |
| Thomas, DL | 1 |
| Bertholom, C | 1 |
| Vcev, A | 1 |
| Bartlett, JG | 2 |
| Kessler, CM | 1 |
| Andersen, J; Bhan, AK; Chung, RT; Graham, CS; Koziel, MJ; Liu, T; Peters, M; Sherman, KE; Wells, A | 1 |
| Cacoub, P; Carrat, F; Deshayes, J; Fafi-Kremer, S; Lunel, F; Morand, P; Payan, C; Perronne, C; Pivert, A; Pol, S | 1 |
| Guéry, B; Yazdanpanah, Y | 1 |
| Dieterich, DT; Park, JS; Saraf, N | 1 |
| Batisse, D; Chaix, ML; Dupont, C; Fontaine, H; Piketty, C; Pol, S; Rouveix, E; Rouzioux, C; Serpaggi, J; Vallet-Pichard, A; Viard, JP; Weiss, L | 1 |
| Lawson, A; Ryder, SD | 1 |
| Laurence, J | 2 |
| Dieterich, DT; Mullen, MP; Patel, MR | 1 |
| Beylot, J; Blanco, P; Bonnet, F; Cazanave, C; Morlat, P; Rakotondravelo, S | 1 |
| Altés, J; Baguena, F; Casanova, A; de Castro, ER; Delejido, A; Garcia, MJ; Rota, R; Sala, M; Santin, M; Shaw, E; Valero, S | 1 |
| Bergin, C; Clarke, S; Farrell, G; Hennessy, M; Hopkins, S; Lambourne, J; McCullagh, L; Mulcahy, F | 1 |
| Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S | 1 |
| Battegay, M; Bernasconi, E; Furrer, H; Hirschel, B; Ledergerber, B; Opravil, M; Rickenbach, M; Schmid, P; Tarr, PE; von Wyl, V; Weber, R; Zinkernagel, AS | 1 |
| Benhamou, Y; Bonnard, P; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Pialoux, G; Schruniger, A; Simon, A; Thibault, V; Valantin, MA | 1 |
| Barrufet, P; Castro, ER; Clotet, B; Coll, S; Force, L; Fuster, D; Galeras, JA; Giménez, MD; Montoliu, S; Montull, S; Planas, R; Sirera, G; Solà, R; Torra, S; Tural, C | 1 |
| de los Santos Gil, I; González Cerrajero, M; Pazos García, A; Sanz Sanz, J | 1 |
| Halota, W; Pawłowska, M | 1 |
| Cullen, C; Grace, M; Hussain, M; Markatou, M; Perelson, AS; Powers, KA; Ribeiro, RM; Talal, AH | 1 |
| Ruiz-Sancho, A; Soriano, V | 1 |
| Bräu, N; Dieterich, DT; Green, J; Hornberger, J; Patel, K; Sulkowski, MS; Torres, MR; Torriani, FJ | 1 |
| Barreiro, P; Garcia-Samaniego, J; Labarga, P; Martín-Carbonero, L; Nuñez, M; Ramos, B; Romero, M; Simarro, N; Soriano, V | 1 |
| Chung, RT; O'Leary, JG | 1 |
| Bagheri, H; Barange, K; Bonnet, E; Claeyssens, S; Guitton, E; Massip, P; Montastruc, JL; Vinel, JP | 1 |
| Capra, F; Franchini, M; Nicolini, N | 1 |
| Ballesteros, AL; Cervantes, M; Clotet, B; Force, L; Fuster, D; García, I; Gonzalez, J; Pedrol, E; Planas, R; Roget, M; Salas, A; Sirera, G; Tor, J; Tural, C; Videla, S; Vilaró, J | 1 |
| Cohen, L; Cooper, MA; Elkashab, M; Feinman, V; Fletcher, D; Girgrah, N; Heathcote, J; Levstik, M; McNaull, WB; Sherman, M; Wong, D; Wong, F; Yim, C | 1 |
| Bessone, F; Corti, M; Findor, J | 1 |
| Daruich, J; Fainboim, H; Frider, B | 1 |
| Mallet, VO; Pol, S | 1 |
| Bhagani, S; Johnson, M; Killingley, B; Slapak, G; Yee, TT | 1 |
| Antela, A; Bárcena, R; Celma, ML; Fernández-Muñoz, R; García-Martos, M; López-San Román, A; Moreno, A; Moreno, L; Moreno, S; Pérez-Elías, MJ; Quereda, C | 1 |
| Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS | 1 |
| Agyemang, AF; Hu, Z; Kottilil, S; McLaughlin, MM; Pau, AK; Polis, MA | 1 |
| Bongiovanni, M; Casanova, F; Ferrero, S; Monforte, Ad; Ranieri, R | 1 |
| Gorman, JM; Weiss, JJ | 1 |
| Arizcorreta, A; Brun, F; Fernández-Gutiérrez, C; Girón-González, JA; Guzmán, EP; Márquez, M; Rodríguez-Iglesias, M | 1 |
| Eyster, ME; Horn, PS; Rouster, SD; Sherman, KE; Shire, NJ; Stanford, S | 1 |
| Fernández-Carbia, A; González-Lassalle, E; Marxuach-Cuétara, AM; Ríos-Bedoya, CF; Rodríguez-Orengo, JF; Rodríguez-Torres, M; Salgado-Mercado, R | 1 |
| Buggisch, P; Clumeck, N; DePamphilis, J; Dieterich, D; Lissen, E; Main, J; Mendes-Correa, M; Montaner, J; Nelson, M; Pessôa, M; Sola, R | 1 |
| Barreiro, P; Garcia-Samaniego, J; Labarga, P; Ruiz-Sancho, A; Soriano, V | 1 |
| Blanco, JL; Costa, J; de Lazzari, E; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martinez, E; Milinkovic, A; Murillas, J; Sánchez-Tapias, JM | 1 |
| Backus, LI; Boothroyd, DB; Mole, LA; Phillips, BR | 1 |
| Boix-Martínez, V; Clemente-Ricote, G; Marco-Mouriño, A; Núñez-Martínez, O; Portilla-Sogorb, J; Reus-Bañuls, S; Saiz de la Hoya-Zamácola, P; Teixidó i Pérez, N | 1 |
| Ballesteros, AL; Clotet, B; Ferrer, MJ; Fumaz, CR; Fuster, D; Gómez, G; Masmitjà, E; Muñoz-Moreno, JA; Paredes, R; Pérez-Alvarez, N; Salas, A; Tural, C | 1 |
| Buenestado-García, J; Egido-García, R; Piñol-Felis, C; Reñé-Espinet, JM; Rubio-Caballero, M; Rubio-Rivas, M | 1 |
| Tural i Llàcher, C | 1 |
| Hu, Z; Kleiner, DE; Koratich, C; Kottilil, S; Lempicki, R; Masur, H; McLaughlin, M; Polis, MA; Rehm, CA; Reitano, KN; Wood, B; Wu, L; Yang, J | 1 |
| Muir, AJ; Ramamurthy, M | 1 |
| Frank, I; Gross, R; Kostman, JR; Lo Re, V; Mounzer, K; Putt, M; Reddy, KR; Rennert, H; Stieritz, DD; Strom, BL; Zemel, BS | 1 |
| Carneiro, F; Chaves, L; Coelho, H; Dias, N; Duarte, M; Fortes, O; Horta, A; Mendez, J; Pinho, L; Pires, N; Recalde, C; Sarmento-Castro, R; Seabra, J; Tavares, AP; Vasconcelos, O; Ventura, A | 1 |
| Aguilar Marucco, D; Bonora, S; Calcagno, A; Cariti, G; Cavecchia, I; de Requena, DG; De Rosa, FG; Di Perri, G; Sinicco, A; Veronese, L | 1 |
| Shafran, SD | 1 |
| Sherman, KE | 2 |
| Alves de Mattos, A; Ferrari de Oliveira Rigo, J; Galperim, B; Lerias de Almeida, PR; Ribeiro de Souza, A; Riegel Santos, B; Valle Tovo, C | 1 |
| Bani-Sadr, F; Chakvetadze, C; Lamontagne, F; Le Pendeven, C; Pialoux, G; Vincensini, JP | 1 |
| Bowers, P; Henry, DH; Lamarca, A; Leitz, G; Slim, J | 1 |
| Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Ocaña, I; Pahissa, A; Ribera, E; Sauleda, S | 1 |
| Allende, H; Bilbao, I; Castells, L; Esteban, JI; Esteban, R; Guardia, J; Len, O; Margarit, C; Pahissa, A; Piron, M; Ribera, E; Sauleda, S; Vargas, V | 1 |
| Barreiro, P; Benito, JM; de Baar, M; de Mendoza, C; González-Lahoz, J; Martin-Carbonero, L; Rodriguez-Novoa, S; Soriano, V; Zahonero, N | 1 |
| Cacoub, P; Carrat, F; Fafi-Kremer, S; Lunel, F; Morand, P; Payan, C; Perronne, C; Pivert, A; Pol, S | 1 |
| Andreu, AL; Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Juarez, A; Ocaña, I; Pahissa, A; Quer, J; Ribera, E; Ruiz, I; Sauleda, S | 1 |
| Sherman, KE; Shire, NJ; Welge, JA | 1 |
| Albo Castaño, MI; Casallo Blanco, S; Marcos Sánchez, F | 1 |
| Dahari, H; Haller, I; Licholai, T; Markatou, M; Perelson, AS; Ribeiro, RM; Talal, AH; Zeremski, M | 1 |
| Javed, U; Lanford, J; Liu, R; Paul, S; Tevendale, R | 1 |
| Brown, QB; Cunningham-Rundles, S; Dorante, G; Markatou, M; Talal, AH; Zeremski, M | 1 |
| Behler, CM; Chung, RT; Lin, F; Peters, MG; Robbins, GK; Vittinghoff, E; Volberding, PA | 1 |
| Amarapurkar, D; Bowden, S; Chow, WC; Chutaputti, A; Dore, G; Gane, E; Guan, R; Hamid, SS; Hardikar, W; Hui, CK; Jafri, W; Jia, JD; Lai, MY; Leung, N; McCaughan, GW; Omata, M; Piratvisuth, T; Sarin, S; Sollano, J; Tateishi, R; Wei, L | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Denoeud, L; Lunel-Fabiani, F; Morand, P; Perronne, C; Pol, S | 1 |
| Barreiro, P; Berdún, MA; Galindo, MJ; Hernandez-Burruezo, JJ; Mariño, A; Martin-Carbonero, L; Miralles, C; Núñez, M; Sola, J; Soriano, V | 1 |
| Arazo, P; Barreiro, P; Berdún, MA; Echevarría, S; Garcia-Samaniego, J; Guardiola, JM; Labarga, P; Losada, E; Miralles, C; Núñez, M; Ocampo, A; Ramos, B; Rendón, A; Romero, M; Santos, I; Soriano, V | 1 |
| Benhamou, Y; Sulkowski, MS | 1 |
| Benhamou, Y; Bräu, N; Cargnel, A; Hatzakis, A; Mauss, S; Peters, M; Pol, S; Puoti, M; Rockstroh, J; Soriano, V; Sulkowski, M | 1 |
| Gagnieu, MC; Maynard, M; Souvignet, C; Trepo, C | 1 |
| Arduino, RC; Barnett, BJ; Bull, L; Torres, HA | 1 |
| Goldmann, G; Kalff, JC; Oldenburg, J; Rockstroh, JK; Sauerbruch, T; Speidel, N; Spengler, U; Vogel, M; Voigt, E; Wojcik, K | 1 |
| Ahlenstiel, G; Berg, T; Biermer, M; Bueren, K; Grünhage, F; Nattermann, J; Nischalke, HD; Rockstroh, J; Sauerbruch, T; Spengler, U; Vogel, M | 1 |
| Alston, B; Aweeka, FT; Chung, RT; Kang, M; Lizak, P; Yu, JY | 1 |
| Bouajram, R; Dorn, A; Kim, AI; Saab, S | 1 |
| Bräu, N; Clumeck, N; Cooper, DA; Dieterich, DT; Dore, GJ; Godofsky, EW; Lamoglia, RS; Lissen, E; Mendes-Correa, MC; Nelson, MR; Rodriguez-Torres, M; Sulkowski, M; Torriani, FJ; Tural, C; Yetzer, E | 1 |
| Buckton, AJ; Fisher, M; James, R; Kulasegaram, R; Ngui, SL; Rangarajan, S; Teo, CG | 1 |
| Benito, JM; Capa, L; Cascajero, A; de Mendoza, C; García-Samaniego, J; González-Lahoz, J; Muñoz, F; Nuñez, M; Romero, M; Soriano, V | 1 |
| Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Blanco, F; Cervantes, M; de los Santos, I; Echeverria, S; Galindo, MJ; García-Samaniego, J; Guardiola, J; Hernandez-Burruezo, JJ; Losada, E; Martin-Carbonero, L; Miralles, C; Nuñez, M; Ocampo, A; San Joaquín, I; Sola, J; Soriano, V | 1 |
| Arizcorreta-Yarza, A; Girón-González, JA; González-Serrano, M; Gutiérrez-Valencia, A; López-Cortés, LF; Macías, J; Mira, JA; Pineda, JA; Santos, I; Torre-Cisneros, J; Valera-Bestard, B; Vergara, S | 1 |
| Axel, B; Berg, T; Bienek, B; Bruno, R; Clotet, B; Danta, M; Grünhage, F; Haerter, G; Klausen, G; Lutz, T; Mayr, C; Nattermann, J; Nischalke, HD; Rausch, M; Rockstroh, JK; Sauerbruch, T; Schewe, K; Spengler, U; Tural, C; Vogel, M | 1 |
| Barreiro, P; Casado, R; Castellares, C; Garcia-Gasco, P; Labarga, P; Maida, I; Martin-Carbonero, L; Pinilla, J; Soriano, V; Vispo, ME | 1 |
| Bani-Sadr, F; Billaud, E; Cacoub, P; Carrat, F; Doll, J; Goderel, I; Penalba, C; Perronne, C; Pol, S; Welker, Y | 1 |
| Dewar, R; Haagmans, B; Jackson, J; Koratich, C; Kottilil, S; Masur, H; McLaughlin, M; Neumann, A; Polis, M; Reitano, K; Rozenberg, L | 1 |
| Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Cervantes, M; de Los Santos, I; Echeverría, S; Galindo, MJ; García-Samaniego, J; Guardiola, JM; Hernandez-Burruezo, JJ; Losada, E; Miralles, C; Núñez, M; Ocampo, A; Romero, M; San Joaquín, I; Sola, J; Soriano, V | 1 |
| Alagna, L; De Bona, A; Galli, L; Gallotta, G; Guzzo, A; Lazzarin, A; Uberti-Foppa, C | 1 |
| Dore, GJ; Hellard, ME; Kaldor, JM; Nguyen, OK | 1 |
| Berenguer, J; Clotet, B; Montes-Ramírez, M; Planas, R; Quereda, C; Rubio, R; Santín, M; Solà, R; Tural, C | 1 |
| Rockstroh, J; Vogel, M | 1 |
| Carrillo-Gómez, R; Collado, A; García-García, JA; Gil, Ide L; Girón-González, JA; Gómez-Mateos, J; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Valera-Bestard, B | 1 |
| Brew, BJ; Dore, GJ; Kaldor, JM; Koorey, DJ; Krahn, MD; Maruff, P; Thein, HH | 1 |
| Basgoz, N; Bica, I; Birch, C; Davis, B; Gandhi, RT; Graeme-Cook, F; McGovern, BH; Quirk, JR; Stone, D; Zachary, K; Zaman, MT | 1 |
| Buzatu, E; Cooper, CL; Dudas, J; Esguerra, R; Gorrell, MD; Haber, PS; Hilzenrat, N; Ionescu, C; Leo, MA; Lieber, CS; McCaughan, GW; Neuman, MG; Ramadori, G; Saile, B; Seth, D; Sha, K; Voiculescu, M; Winkler, RE; Wyse, J; Zakhari, S | 1 |
| Afdhal, NH; Brinkley, SC; de Oca, RM; Higgins, Y; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL; Torbenson, MS | 1 |
| Alcocer, F; Bonet, L; Cordero, M; García-Samaniego, J; López-Serrano, P; Mariño, A; Martin-Carbonero, L; Nuñez, M; Portu, J; Soriano, V | 1 |
| Abbate, I; Capobianchi, MR; D'Offizi, G; Dianzani, F; Martini, F; Narciso, P; Rozera, G | 1 |
| Blanc, D; Carrieri, MP; Dellamonica, P; Marcellin, F; Préau, M; Ravaux, I; Spire, B | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Duclos-Vallée, JC; Féray, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M; Teicher, E; Vittecoq, D | 1 |
| Clotet, B; Clumeck, N; Cooper, DA; Depamphilis, J; Dieterich, DT; Montaner, J; Opravil, M; Rockstroh, JK; Sasadeusz, J; Torriani, FJ | 1 |
| Dellamonica, P; Freedberg, KA; Gastaut, JA; Marimoutou, C; Poizot-Martin, I; Pradier, C; Rosenthal, E; Tran, A; Valerio, L; Yazdanpanah, Y | 1 |
| Carriero, D; Dieterich, DT; Rafiq, N; Uriel, A | 1 |
| Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M | 1 |
| Aguirrebengoa, K; Asensi, V; Barreiro, P; Cervantes, M; Echeverria, S; Garcia-Samaniego, J; Núñez, M; Ocampo, A; Pascual, A; Soriano, V | 1 |
| Brann, T; Dewar, RL; Highbarger, HC; Imamichi, T; Koratich, C; Kottilil, S; Lempicki, RA; Masur, H; McLaughlin, M; Neumann, AU; Nussenblatt, V; Polis, MA; Proschan, M; Rehm, CA; Yang, J | 1 |
| Avidan, B; Bar-Meir, S; Bashari, D; Lurie, Y; Maor, Y; Martinowitz, U; Paritsky, M; Rachlis, Z; Safadi, R; Schapiro, JM; Segol, O | 1 |
| Iushchuk, ND; Ivanova, LM; Kravchenko, AV; Maksimova, SL; Morgunova, NM; Ol'shanskiĭ, AIa; Serebrovskaia, LV | 1 |
| Bergin, C; Codd, M; Farrell, G; Mulcahy, F; Norris, S; Shea, DO; Tuite, H | 1 |
| Aguilar Marucco, D; Baietto, L; Bonasso, M; Bonora, S; Cariti, G; D'Avolio, A; De Blasi, T; Di Perri, G; Gonzalez de Requena, D; Sciandra, M; Siccardi, M; Sinicco, A; Tettoni, C; Trentini, L | 1 |
| Crespo, M; Curran, A; Esteban, JI; Falcó, V; Feijoo, M; Lopez, R; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Sauleda, S; Villar del Saz, S | 1 |
| Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B | 1 |
| Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; De Boever, CM; Halfon, P; Lapidus, N; Perronne, C; Pol, S | 1 |
| Cogliano-Shutta, NA; Connors, M; Davey, RT; Hallahan, CW; Johnson, AJ; Kottilil, S; Lempicki, RA; Lifson, JD; Luskin, MR; Manion, MM; Metcalf, JA; Mican, JM; Patamawenu, AA; Tilton, JC | 1 |
| Annable, L; Benkelfat, C; Brouillette, MJ; Cooper, C; Klein, MB; Kraus, D; Sheehan, NL; Singer, J; Weston, F | 1 |
| Chougnet, C; Fichtenbaum, CJ; Lages, CS; Shata, MT; Velilla, PA; Ying, J | 1 |
| Ammassari, A; Giuliani, M; Lacaita, MG; Lajolo, C; Sartorio, A; Scivetti, M; Tamburrini, E; Tumbarello, M | 1 |
| Bani-Sadr, F; Bensalem, M; Cacoub, P; Carrat, F; Lapidus, N; Melchior, JC; Perronne, C; Pol, S; Ravaux, I; Rosa, I | 1 |
| Agud, JM; Apraiz, L; Portu, J; Tarabini-Castellani, P | 1 |
| Coriat, R; Podevin, P | 1 |
| Bergamaschi, V; Borghi, F; Carosi, G; Cologni, G; Gatti, F; Matti, A; Nasta, P; Puoti, M; Ricci, A | 1 |
| Karlström, O; Sönnerborg, A; Weiland, O | 1 |
| Carriero, D; Dieterich, DT; Fabrizi, F; Martin, P; Park, J; Uriel, AJ | 1 |
| Collado, A; de los Santos, I; del Valle, J; García-García, JA; Girón, JA; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A | 1 |
| Ferenci, P; Gangl, A; Peck-Radosavljevic, M; Rasoul-Rockenschaub, S; Reiberger, T; Rieger, A | 1 |
| Alaeus, A; Falconer, K; Gonzalez, VD; Michaëlsson, J; Moll, M; Reichard, O; Sandberg, JK | 1 |
| Black-Payne, C; Bocchini, J; King, JW; Stogner, SW | 1 |
| Bellini, WJ; Mustafa, MM; Siegel, JD; Timmons, CF; Weitman, SD; Winick, NJ | 1 |
| Bassiakos, Y; Booth, D; Clax, PA; Connor, JD; Cooney, E; Crumpacker, CS; Erice, A; Griffith, BP; Holden-Wiltse, J; Hussey, S; Japour, AJ; Johanneson, N; Lertora, JJ; McLaren, C; Meehan, PM; Pollard, R; Timpone, J; Walesky, M; Wood, K | 1 |
| Bergeron, MG; Bernier, R; Tremblay, M; Tsoukas, C | 1 |
| Bruguera, M | 1 |
| Pol, S; Zylberberg, H | 1 |
| Bricaire, F | 1 |
| Dieterich, DT; Purow, JM; Rajapaksa, R | 1 |
| Goebel, FD; Jablonowski, H | 1 |
| Dieterich, DT | 2 |
| Moberg, L; Schvarcz, R; Sönnerborg, A | 1 |
| Batisse, D; Kazatchkine, MD; Landau, A; Piketty, C | 1 |
| Arribas, JR; García-Samaniego, J; González, J; Peña, JM; Pérez-Olmeda, M; Soriano, V | 1 |
| Batisse, D; Belec, L; Bloch, F; Duong Van Huyen, JP; Kazatchkine, MD; Landau, A; Petite, JP; Pialoux, G; Piketty, C; Weiss, L | 1 |
| Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C | 1 |
| Batisse, D; Jian, R; Kazatchkine, MD; Landau, A; Piketty, C | 1 |
| Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H | 1 |
| García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Romero, M; Soriano, V | 1 |
| Castéra, L; Roulot, D | 1 |
| Chadapaud, S; Hittinger, G; Lafeuillade, A | 1 |
| Cadorin, L; di Gennaro, G; Nasti, G; Rizzardini, G; Tirelli, U | 1 |
| Dieterich, D | 1 |
| Powell, J | 1 |
| Stoia, J | 1 |
| Norton, M | 1 |
| Grinberg, L | 1 |
| James, JS | 1 |
| Lauer, GM; Walker, BD | 1 |
| Hubbard, MJ | 1 |
| Kawabe, T; Toda, G | 1 |
| Cadorin, L; Carbone, A; Di Gennaro, G; Nasti, G; Talamini, R; Tavio, M; Tedeschi, RM; Tirelli, U | 1 |
| García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Soriano, V | 1 |
| Altisent, C; Esteban, JI; Esteban, R; Guardia, J; Juárez, A; Puig, L; Ruiz, I; Sauleda, S | 1 |
| Batisse, D; Belec, L; Bloch, F; Bruneval, P; Duong Van Huyen, JP; Jian, R; Kazatchkine, MD; Landau, A; Piketty, C; Weiss, L | 1 |
| Cotler, SJ; Jensen, DM | 1 |
| Bain, VG | 1 |
| Dieterich, DT; Jones, JS | 1 |
| Murphy, MJ | 1 |
| Canchis, PW; Jacobson, I; Talal, AH | 1 |
| Tossing, G | 1 |
| García-Samaniego, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Romero, M; Soriano, V | 1 |
| Bonacini, M | 1 |
| Zeuzem, S | 1 |
| Cooper, DA; Dore, GJ | 1 |
| Fukuda, Y; Hayashi, K; Nakano, I; Takamatsu, J; Toyoda, H | 1 |
| Esteban, JI; Juárez, A; Sauleda, S | 1 |
| Ray, SC; Sulkowski, MS; Thomas, DL | 1 |
| Gebo, K | 1 |
| Bruno, R; Ciappina, V; Cotler, S; Filice, G; Rondanelli, M; Sacchi, P | 1 |
| Fernandez, H; Smith, RA | 1 |
| De Clercq, E | 1 |
| Heseltine, PN; Hollinger, FB; Johnson, KM; Laurence, J; Lubina, JA; Makuch, RW; Parks, WP; Rasheed, S; Roberts, RB | 1 |
| Courtless, J; LeLacheur, S; Meyer, WA; Parenti, DM; Paxton, H; Schlesselman, SB; Schulof, RS; Simon, GL; Sztein, MB | 1 |
| Forsythe, AB | 1 |
| Jurica, K; Makuch, RW; Meyer, WA; Paxton, H; Roberts, RB | 1 |
| Makuch, RW; Roberts, RB | 1 |
| Bodsworth, N; Cooper, DA | 1 |
145 review(s) available for ribavirin and HIV Coinfection
| Article | Year |
|---|---|
Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
Topics: Animals; Anti-Retroviral Agents; Antineoplastic Agents; HIV Infections; Humans; Male; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2018 |
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Renal Insufficiency, Chronic; Ribavirin | 2017 |
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Treatment of hepatitis C in special populations.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Immunocompromised Host; Interferons; Liver Transplantation; Postoperative Period; Protease Inhibitors; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2018 |
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Guanine; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
[Telaprevir in treatment-naïve patients with HCV monoinfection].
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Young Adult | 2013 |
[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Topics: Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2013 |
Optimizing treatment in HIV/HCV coinfection.
Topics: Anti-Retroviral Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin | 2013 |
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals.
Topics: Antiviral Agents; Coinfection; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin | 2013 |
Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.
Topics: Anti-Retroviral Agents; Comorbidity; Disease Management; Disease Progression; End Stage Liver Disease; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Factors influencing adherence in Hepatitis-C infected patients: a systematic review.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Medication Adherence; Polyethylene Glycols; Ribavirin | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication | 2014 |
Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.
Topics: Acute Disease; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Regimens for Patients Coinfected with Human Immunodeficiency Virus.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins | 2015 |
Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome | 2016 |
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Antiviral Agents; Coinfection; Drug Users; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sustained Virologic Response; Viral Load; Young Adult | 2016 |
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Hepatitis C: efficacy and safety in real life.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Management of chronic hepatitis C virus infection in HIV-infected patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2008 |
Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Oral lichenoid lesions in HIV-HCV-coinfected subjects during antiviral therapy: 2 cases and review of the literature.
Topics: Antiviral Agents; Diagnosis, Differential; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lichen Planus, Oral; Lichenoid Eruptions; Male; Middle Aged; Mouth Diseases; Mouth Mucosa; Ribavirin | 2008 |
Clinical management of HIV/hepatitis C virus coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Health Services Needs and Demand; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Medication Adherence; Nurse Practitioners; Nurse's Role; Ribavirin; Risk Factors; Severity of Illness Index; Social Support | 2008 |
A review of current anti-HCV treatment regimens and possible future strategies.
Topics: Antiviral Agents; Clinical Trials as Topic; DNA-Directed RNA Polymerases; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2009 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?
Topics: Alcoholism; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Medication Adherence; Ribavirin | 2009 |
[Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2009 |
Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Treatment of acute hepatitis C in HIV-positive individuals: what are the challenges?
Topics: Acute Disease; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral | 2009 |
Acute hepatitis C and HIV coinfection.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2010 |
The treatment of chronic hepatitis C virus infection in HIV co-infection.
Topics: Antiretroviral Therapy, Highly Active; Coinfection; Europe; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2009 |
Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors | 2010 |
Management of HIV and hepatitis virus coinfection.
Topics: Animals; Antiretroviral Therapy, Highly Active; Disease Management; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Prevalence; Randomized Controlled Trials as Topic; Ribavirin | 2011 |
[Current status of acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Asymptomatic Diseases; Comorbidity; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Risk Factors; RNA, Viral; Sexual Behavior; Spain; Substance Abuse, Intravenous; Viremia | 2011 |
[Treatment of hepatitis C virus in HIV-positive patients].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Outbreaks; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Patient Dropouts; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2011 |
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Topics: Antiviral Agents; Confidence Intervals; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Probability; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Risk Assessment; State Medicine; Treatment Outcome; Uncertainty; United Kingdom | 2011 |
Treatment of acute hepatitis C infection in HIV-infected patients.
Topics: Antiviral Agents; Australia; Cohort Studies; Drug Monitoring; Europe; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferons; Male; Ribavirin; Treatment Outcome; United States | 2011 |
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
Interferon combination therapy for HIV/hepatitis C virus coinfection.
Topics: Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Host genetics.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2011 |
The role of insulin resistance in HIV/hepatitis C virus-coinfected patients.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Insulin Resistance; Interferon-alpha; Polyethylene Glycols; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
HIV and hepatitis C co-infection: acute HCV therapy.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Hepatitis C virus-human immunodeficiency virus coinfection.
Topics: Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load | 2012 |
[Progress in blood purification medicine in 2011].
Topics: Antiviral Agents; Bone Diseases, Metabolic; Cardiovascular Diseases; Chronic Disease; Hepatitis C; HIV Infections; Humans; Interferons; Kidney Diseases; Practice Guidelines as Topic; Renal Dialysis; Ribavirin | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Acute hepatitis C in patients with HIV.
Topics: Antiviral Agents; Australia; Coinfection; Europe; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin; United States | 2012 |
Acute hepatitis C in an HIV-infected patient: a case report and review of literature.
Topics: Acute Disease; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
Boceprevir and treatment of chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2013 |
HCV therapy in HIV-infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
Management of hepatitis C in human immunodeficiency virus-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2002 |
HCV chronic hepatitis in patients with HIV: clinical management issues.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Ribavirin; Time Factors | 2002 |
Hepatitis C and HIV co-infection: a review.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Immunity, Cellular; Interferons; Male; Ribavirin | 2002 |
[Chronic hepatitis C in HIV-HCV coinfected patients].
Topics: Adult; Age Factors; Amantadine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Meta-Analysis as Topic; Pilot Projects; Prevalence; Ribavirin; Risk Factors | 2002 |
[Management of patients with hepatitis C virus infection. Virological tests].
Topics: Acute Disease; Adult; Algorithms; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Biomarkers; Capsid; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Male; Monitoring, Physiologic; Polymerase Chain Reaction; Prognosis; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2002 |
[Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Liver Transplantation; Male; Multicenter Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Time Factors; Transaminases | 2002 |
[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Didanosine; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Life Style; Mitochondria; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Viral Load; Zidovudine | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
Progressive vaccinia.
Topics: Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Methisazone; Organophosphonates; Organophosphorus Compounds; Ribavirin; Vaccination; Vaccinia | 2003 |
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
Topics: Adsorption; Antiviral Agents; Black People; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Treatment of chronic hepatitis C in patients coinfected with HIV-HCV/HBV].
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Synergism; Hepatitis C; HIV Infections; Humans; Metabolic Clearance Rate; Pancreatitis; Ribavirin | 2003 |
HIV and hepatitis C co-infection.
Topics: Antiviral Agents; Comorbidity; Contraindications; Drug Combinations; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Viral hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index | 2003 |
HIV and HCV coinfection in haemophilia.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Ribavirin; Transaminases; Viremia | 2004 |
Care of patients with hepatitis C and HIV co-infection.
Topics: Anti-Retroviral Agents; Antiviral Agents; Hepatitis C; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Therapy of hepatitis C in HIV-coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Europe; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Ribavirin; United States | 2004 |
Therapy of chronic hepatitis C virus infection in HIV co-infected people.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2004 |
Treatment of the hepatitis C virus in patients coinfected with HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
[Hepatitis C in the HIV-infected person].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Prognosis; Ribavirin; Temperance | 2004 |
[Treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hungary; IMP Dehydrogenase; Interferons; Liver Cirrhosis; Liver Transplantation; Nucleosides; Ribavirin; Risk Factors | 2004 |
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin | 2004 |
Viral error catastrophe by mutagenic nucleosides.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Models, Genetic; Mutagenesis; Nucleosides; Ribavirin; RNA Viruses | 2004 |
Anemia during treatment of hepatitis C in HIV-infected patients.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Molecular Weight; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
HIV/HCV coinfection in clinical practice.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States | 2004 |
Hepatitis C in haemophiliacs.
Topics: Female; Genotype; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin; Time Factors; Treatment Outcome | 2004 |
Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation.
Topics: Antiviral Agents; Growth Substances; Hematologic Diseases; Hematopoiesis; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; United States | 2005 |
[HIV infections].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Transmission, Infectious; Hepatitis C; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Interferons; Patient Compliance; Ribavirin; Treatment Failure | 2004 |
Therapeutic modalities in hepatitis C: challenges and development.
Topics: Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Quality of Life; Ribavirin | 2005 |
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
Topics: Abnormalities, Drug-Induced; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Female; Hematologic Diseases; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Male; Ribavirin | 2005 |
Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Update on hepatitis C treatment in HIV-coinfected patients.
Topics: Algorithms; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin | 2004 |
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions.
Topics: Drug Interactions; HIV Infections; Humans; Hydroxyurea; Membrane Transport Proteins; Nucleosides; Nucleotides; Reverse Transcriptase Inhibitors; Ribavirin | 2004 |
Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
[Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin; Risk Factors | 2004 |
[Treatment of chronic hepatitis C virus infection in human immunodeficiency virus (HIV) infected patients].
Topics: Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain | 2005 |
Treatment of hepatitis C virus/HIV coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Treatment Refusal | 2005 |
HIV and liver diseases: recent clinical advances.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Ribavirin | 2005 |
Treatment of hepatitis C virus in HIV patients: a review.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
New paradigms in the management of HIV and hepatitis C virus coinfection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
New drug targets for HIV and hepatitis C virus coinfection.
Topics: Drug Delivery Systems; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferons; Ribavirin; Viral Hepatitis Vaccines; Virus Replication | 2005 |
Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Options for treatment of hepatitis C in HIV-infected persons.
Topics: Antiviral Agents; Drug Carriers; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Treatment algorithm for the management of hepatitis C in HIV-coinfected persons.
Topics: Algorithms; Anti-Retroviral Agents; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Management of hepatitis C/HIV coinfection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2006 |
Update on liver disease in hemophilia patients.
Topics: Antiviral Agents; Factor VII; Factor VIIa; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2006 |
[Antiretroviral drugs in severe acute respiratory syndrome].
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Pyrimidinones; Ribavirin; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Viral Fusion Proteins | 2006 |
HBV plus HCV, HCV plus HIV, HBV plus HIV.
Topics: Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Drug Interactions; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors | 2006 |
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Topics: Acute Disease; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
[Chronic hepatitis C--patients "difficult to treat"].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[HIV and HCV coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Contraindications; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Multicenter Studies as Topic; Patient Selection; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2006 |
Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Monitoring; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Patient Selection; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Failure | 2006 |
Management of hepatitis C virus coinfection in HIV-infected persons.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2006 |
Treatment of hepatitis C in hemophiliacs.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon Type I; Liver Transplantation; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
Topics: Algorithms; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Improving anti-hepatitis C virus therapy.
Topics: Algorithms; Animals; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2006 |
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV.
Topics: Antidepressive Agents; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Patient Compliance; Polyethylene Glycols; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2006 |
Treatment of hepatitis C in special populations.
Topics: Adult; Antiviral Agents; Asian; Black or African American; Hepacivirus; Hepatitis C; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon Type I; Recombinant Proteins; Ribavirin | 2007 |
New paradigms in the management of hepatitis C virus co-infections.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Virus Replication | 2007 |
Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Case Management; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2007 |
Therapeutic issues in HIV/HCV-coinfected patients.
Topics: Anemia; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Liver Transplantation; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Ribavirin; Transaminases | 2007 |
The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Management and therapy of chronic hepatitis C virus infection in HIV-infected individuals.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Patient Compliance; Ribavirin; Treatment Outcome | 2007 |
Inflammation and repair in viral hepatitis C.
Topics: Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Risk Factors | 2008 |
Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature.
Topics: Adult; Base Sequence; Child, Preschool; Encephalitis; Female; Hemophilia A; HIV Infections; Humans; Immunocompromised Host; Male; Measles; Measles virus; Molecular Sequence Data; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribavirin; Time Factors | 1993 |
[Treatment of chronic hepatitis C: still many problems pending].
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cholagogues and Choleretics; Chronic Disease; Clinical Enzyme Tests; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Indomethacin; Interferons; Ofloxacin; Phlebotomy; Recurrence; Ribavirin; Time Factors; Ursodeoxycholic Acid | 1997 |
[Interactions between the human immunodeficiency virus and hepatitis C virus].
Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prevalence; Ribavirin; Virus Replication | 1998 |
Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
Hepatitis C virus infection.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Transplantation; Prevalence; Ribavirin; Transfusion Reaction | 2001 |
Evaluation and management of the patient co-infected with human immunodeficiency virus and hepatitis C.
Topics: Antiviral Agents; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin | 2001 |
[Treatment of chronic hepatitis C patients complicated with the other disease].
Topics: Collagen Diseases; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2001 |
Management of hepatitis C in HIV-infected persons.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Disease Transmission, Infectious; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Neoplasms; Recurrence; Ribavirin | 2001 |
Treatment of hepatitis C virus and HIV co-infections.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; Time Factors | 2001 |
Effect of HCV viral dynamics on treatment design: lessons learned from HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Viremia | 2001 |
The HCV and HIV coinfected patient: what have we learned about pathophysiology?
Topics: Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin; RNA, Viral | 2002 |
Bullet points: new topics in HIV/AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Lipids; Protease Inhibitors; Ribavirin | 2002 |
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Liver; Ribavirin; Viremia | 2001 |
[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].
Topics: Anti-HIV Agents; Antibiosis; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Flaviviridae Infections; GB virus C; Hemophilia A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; HIV-1; Humans; Interferons; Lamivudine; Liver Neoplasms; Liver Transplantation; Prognosis; Ribavirin | 2002 |
[Treatment of chronic hepatitis C in patients with HIV-coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2002 |
Challenges for hepatitis C patients coinfected with HIV.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Hepatitis C; HIV Infections; Humans; Ribavirin | 2002 |
172 trial(s) available for ribavirin and HIV Coinfection
| Article | Year |
|---|---|
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Immunologic Factors; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Topics: Adult; Antiviral Agents; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferon Type I; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Genotype; Germany; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mutant Proteins; Mutation, Missense; Oligopeptides; Prevalence; Ribavirin; Treatment Failure; United Kingdom; Viral Nonstructural Proteins | 2018 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate | 2018 |
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2019 |
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult | 2013 |
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Plasma; Pyridines; Ribavirin; Ritonavir | 2014 |
Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.
Topics: Adult; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure | 2014 |
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2014 |
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pilot Projects; Pioglitazone; Retreatment; Ribavirin; RNA, Viral; Thiazolidinediones; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome; United States | 2014 |
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Topics: Adult; Anemia; Antiviral Agents; Cell Count; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2015 |
OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Topics: Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Italy; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2015 |
Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin | 2015 |
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
The ARRIBA concept: adequate resorption of ribavirin.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Coinfection; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
Topics: Adult; Aged; Animals; Anti-Retroviral Agents; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Leucine; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load; Viremia; Young Adult | 2015 |
Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
Topics: Adult; Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Ribavirin; Tandem Mass Spectrometry | 2015 |
Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; DNA, Circular; DNA, Viral; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Viral Load; Virus Integration; Virus Replication | 2015 |
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2015 |
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult | 2015 |
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.
Topics: Adult; Antiviral Agents; Biomarkers; Bone Remodeling; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.
Topics: Adult; Antiviral Agents; Body Fluid Compartments; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2016 |
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome | 2015 |
Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Immunologic Factors; Interferon-alpha; Interferons; Leukocytes, Mononuclear; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles | 2016 |
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; CD4-Positive T-Lymphocytes; Coinfection; Female; Hepacivirus; HIV Infections; Humans; Immunologic Memory; Interferons; Lipopolysaccharide Receptors; Lymphocyte Activation; Male; Middle Aged; Monocytes; Ribavirin; Young Adult | 2016 |
[In HIV-HCV co-infection check for drug interactions].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Spain; Treatment Outcome; Viral Nonstructural Proteins | 2016 |
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Young Adult | 2017 |
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
Topics: Adult; Aged; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Ribavirin; Treatment Outcome; Valine; Viral Load | 2017 |
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opportunistic Infections; Recombinant Proteins; Ribavirin | 2008 |
Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Replication | 2008 |
Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome | 2008 |
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; DNA Virus Infections; Drug Therapy, Combination; Female; Flaviviridae Infections; GB virus C; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Torque teno virus; Virus Diseases | 2008 |
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Blood Coagulation Disorders, Inherited; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Topics: Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hospitals; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2009 |
Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy.
Topics: Drug Therapy, Combination; gamma-Glutamyltransferase; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2009 |
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Nucleic Acid Amplification Techniques; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2009 |
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.
Topics: Adult; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Liver Diseases; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2009 |
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Topics: Adult; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Epoetin Alfa; Erythrocytes; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Case-Control Studies; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult | 2010 |
Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
Topics: ADP-ribosyl Cyclase 1; Antiviral Agents; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Treatment Outcome; Viral Load | 2010 |
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure | 2011 |
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biomarkers; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Prevalence; Ribavirin; Severity of Illness Index; Vitamin D; Vitamin D Deficiency | 2011 |
Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Black or African American; Drug Administration Schedule; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication; Young Adult | 2011 |
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.
Topics: Alleles; Cohort Studies; Coinfection; Drug Synergism; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Probability; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
Topics: Adult; Dose-Response Relationship, Drug; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Safety; Treatment Outcome | 2012 |
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Topics: Adult; Albumins; Antiviral Agents; Cohort Studies; Coinfection; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin | 2012 |
Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.
Topics: Adult; Analysis of Variance; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon-alpha; Lipid Metabolism; Lipoproteins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin | 2012 |
Hepatitis C treatment outcomes in Australian clinics.
Topics: Adult; Antiviral Agents; Australia; Body Mass Index; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.
Topics: Adult; Antiviral Agents; CD56 Antigen; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Killer Cells, Natural; Lipopolysaccharide Receptors; Male; Polyethylene Glycols; Receptors, IgG; Recombinant Proteins; Ribavirin | 2012 |
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study.
Topics: Antiviral Agents; Coinfection; Depression; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin | 2012 |
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.
Topics: Adult; Female; Gene Expression Regulation, Viral; Genetic Variation; Genotype; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Models, Genetic; Models, Statistical; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins | 2012 |
Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
Topics: Adult; Antiviral Agents; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Tuberculin | 2002 |
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2003 |
T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Case-Control Studies; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Drug Administration Schedule; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Viral Load | 2003 |
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2003 |
Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prognosis; Prospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Withholding Treatment | 2003 |
Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2003 |
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Virus Replication | 2003 |
Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.
Topics: Adult; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
Topics: Adult; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure | 2004 |
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral | 2004 |
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hematologic Diseases; Hemorrhage; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2004 |
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors | 2004 |
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2005 |
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Middle Aged; Patient Dropouts; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets | 2005 |
Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2005 |
Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial.
Topics: Adult; Antiviral Agents; Cohort Studies; Double-Blind Method; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2005 |
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Failure | 2005 |
Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome | 2005 |
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Topics: Adult; Area Under Curve; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Zidovudine | 2005 |
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease-Free Survival; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Hepacivirus; Hepatitis C; Hepatitis C Antigens; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins | 2006 |
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Ribavirin; Tenofovir | 2006 |
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Topics: Acute Disease; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
Topics: Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2006 |
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Topics: Adult; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Zidovudine | 2006 |
Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
Topics: Adult; Antiviral Agents; Darbepoetin alfa; Drug Administration Schedule; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiviral Agents; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Remission Induction; Ribavirin; RNA, Viral; Viral Load | 2006 |
Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2006 |
Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
Topics: Adolescent; Adult; Antiviral Agents; Cell Nucleus; DNA; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin | 2007 |
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemokines, CXC; Drug Administration Schedule; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
Topics: Adult; Antiviral Agents; Hematologic Diseases; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Maximum Tolerated Dose; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Endpoint Determination; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Species Specificity; Treatment Outcome | 2007 |
The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.
Topics: Adult; Aged; Antiviral Agents; Cytosine; Drug Therapy, Combination; Female; Genotype; GTP-Binding Protein beta Subunits; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Thymine; Treatment Outcome | 2007 |
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Cell Line, Tumor; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-6; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; STAT3 Transcription Factor; Treatment Outcome | 2007 |
Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Zidovudine | 2007 |
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
Topics: Adult; Antiviral Agents; Australia; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interviews as Topic; Male; Middle Aged; Patient Care Team; Patient Compliance; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Socioeconomic Factors; Substance Abuse, Intravenous; Time Factors; Treatment Outcome | 2007 |
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Spain; Treatment Outcome; Viral Load | 2007 |
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2008 |
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Withholding Treatment; Zidovudine | 2008 |
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Canada; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Psychometrics; Recombinant Proteins; Ribavirin; Sample Size; Severity of Illness Index; Treatment Outcome | 2008 |
Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Weight Loss | 2008 |
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Renal Dialysis; Renal Insufficiency; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients. The Ribavirin ARC Study Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Proportional Hazards Models; Ribavirin | 1993 |
A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Genetic Variation; Giant Cells; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Viremia | 1996 |
Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin | 1997 |
Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Antiviral Agents; Cost-Benefit Analysis; Daunorubicin; Doxorubicin; Hepatitis C, Chronic; Herpesvirus 8, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sarcoma, Kaposi | 1999 |
Effect of interferon and ribavirin on HIV viral load.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Ribavirin; Viral Load | 2000 |
Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Recombinant Proteins; Ribavirin | 1999 |
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2001 |
Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Blood Coagulation Disorders; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2001 |
Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2001 |
Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Spanish Ribavirin Trial Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Analysis of Variance; CD4-Positive T-Lymphocytes; Double-Blind Method; Female; Follow-Up Studies; Hemoglobins; HIV Infections; Humans; Leukocyte Count; Life Tables; Male; Ribavirin | 1991 |
A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group.
Topics: Administration, Oral; Adolescent; Adult; AIDS-Related Complex; Double-Blind Method; Female; Gene Products, gag; HIV; HIV Antigens; HIV Core Protein p24; HIV Infections; Humans; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ribavirin; Ribonucleosides; RNA-Directed DNA Polymerase; United States; Viral Core Proteins | 1990 |
Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; HIV; HIV Infections; Humans; Inosine; Inosine Pranobex; Killer Cells, Natural; Leukocyte Count; Male; Ribavirin; Ribonucleosides; T-Lymphocytes, Regulatory | 1990 |
Clinical trial of oral ribavirin.
Topics: Administration, Oral; HIV Infections; Humans; Ribavirin | 1991 |
A phase 1 study of ribavirin in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Complex; Drug Evaluation; Drug Tolerance; Gene Products, gag; Hematocrit; HIV Core Protein p24; HIV Infections; Homosexuality; Humans; Leukocyte Count; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Ribavirin; Ribonucleosides; Viral Core Proteins | 1990 |
562 other study(ies) available for ribavirin and HIV Coinfection
| Article | Year |
|---|---|
Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.
Topics: Antiviral Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.
Topics: Adult; Antibodies, Neutralizing; Antirheumatic Agents; Antiviral Agents; Cell Line, Tumor; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Retrospective Studies; Ribavirin; Sustained Virologic Response; Viral Load | 2019 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Treatment Outcome | 2020 |
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Italy; Male; Middle Aged; Pyrrolidines; Regression Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Patient Selection; Polyethylene Glycols; Retrospective Studies; Ribavirin; South Africa; Treatment Outcome | 2020 |
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
Topics: Antiviral Agents; Bone Density; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2021 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Topics: Adult; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Ribavirin monotherapy for the treatment of chronic hepatitis E in an immunosuppressed patient.
Topics: Antiviral Agents; Hepatitis E; HIV Infections; Humans; Immunocompromised Host; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2021 |
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China.
Topics: Adult; Antiviral Agents; China; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Ribavirin; Rural Population; Sofosbuvir; Sustained Virologic Response | 2021 |
Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Immune Tolerance; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes, Regulatory; Viral Load | 2021 |
Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C.
Topics: Adult; Antiviral Agents; Coinfection; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin | 2017 |
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation | 2017 |
Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Coinfection; Drug Combinations; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lamivudine; Lopinavir; Male; Models, Immunological; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Ribavirin; Ritonavir; Time-to-Treatment; Zidovudine | 2017 |
Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Topics: Adaptive Immunity; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Coinfection; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2017 |
Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Coinfection; Hepatitis B; Hepatitis E; Hepatitis E virus; Hepatitis, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Viral Load | 2017 |
HCV antigen instead of RNA testing to diagnose acute HCV in patients treated in the Dutch Acute HCV in HIV Study.
Topics: Adult; Hepatitis C; Hepatitis C Antigens; HIV Infections; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sensitivity and Specificity | 2017 |
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Health Services; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Program Development; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Ukraine; Young Adult | 2017 |
Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit.
Topics: Antiviral Agents; Cryoglobulinemia; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Ribavirin | 2017 |
Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Retrospective Studies; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2017 |
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Thailand; Treatment Outcome; Viral Load | 2018 |
Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; Disease Reservoirs; DNA, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Viral Load | 2018 |
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Spain; Treatment Outcome; Young Adult | 2018 |
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.
Topics: 2-Naphthylamine; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2018 |
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Ritonavir; Sofosbuvir; Treatment Outcome | 2018 |
Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.
Topics: Adult; Biomarkers; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Proteomics; Ribavirin; Treatment Outcome | 2019 |
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Quinoxalines; Ribavirin; Sexual and Gender Minorities; Sulfonamides | 2019 |
Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Topics: Adult; Antiviral Agents; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prisons; Retrospective Studies; Ribavirin; Taiwan; Viral Load | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Coinfection; Disease Progression; DNA, Mitochondrial; Europe; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk | 2019 |
The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2013 |
Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Immunity, Active; Interferon-alpha; Lymph Nodes; Ribavirin | 2013 |
UNITAID can address HCV/HIV co-infection.
Topics: Anti-Retroviral Agents; Antiviral Agents; Developing Countries; Financial Support; Hepatitis C; HIV Infections; Humans; Interferon-alpha; International Agencies; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Cardiovascular Diseases; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Practice Guidelines as Topic; Ribavirin; Young Adult | 2013 |
Chronic hepatitis E resolution in a human immunodeficiency virus (HIV)-infected patient treated with ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis E; Hepatitis, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin.
Topics: Acute Disease; Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Topics: Amino Acid Sequence; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Molecular Sequence Data; Nitro Compounds; Polyethylene Glycols; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Thiazoles; Treatment Failure; Viral Nonstructural Proteins | 2013 |
IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Receptors, Cytokine; Retrospective Studies; Ribavirin; Treatment Failure | 2013 |
Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Middle Aged; Neutropenia; Opportunistic Infections; Prospective Studies; Ribavirin; Risk Assessment | 2013 |
Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin.
Topics: Antiviral Agents; Hepatitis E; Hepatitis, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome | 2013 |
HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Saliva; Viral Load | 2014 |
[Thrombotic thrombocytopenic purpura associated with interferon therapy in a HIV and HCV co-infected woman].
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Ribavirin | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypophosphatemia; Interferons; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Ribavirin; Risk Factors; Tenofovir | 2013 |
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, LDL; Ribavirin; Treatment Outcome | 2013 |
Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Blood Coagulation Disorders; Blood Transfusion; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Transfusion Reaction; Young Adult | 2013 |
In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Viral Load; Vitamin D | 2013 |
Boceprevir for HCV in patients with HIV: where next?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
Topics: Antiviral Agents; Cluster Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, DNA | 2013 |
HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Female; Follow-Up Studies; Genotyping Techniques; Hepatitis C, Chronic; Histocompatibility Antigens Class I; HIV Infections; HLA-E Antigens; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.
Topics: Adult; Alleles; Cohort Studies; Coinfection; Female; Gene Frequency; Genetic Loci; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, KIR; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2013 |
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Severity of Illness Index; United States; Withholding Treatment | 2013 |
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Poisson Distribution; Prospective Studies; Ribavirin | 2013 |
Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Aged; Antiviral Agents; Brazil; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2013 |
Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Fatigue; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Mental Health; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2013 |
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
Topics: Antiviral Agents; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome | 2013 |
Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome; Viral Load | 2013 |
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Viral Load | 2014 |
Relapse of hepatitis C in three immunocompetent patients achieved a sustained virological response following interferon-based antiviral therapy.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2013 |
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukins; Male; Polymorphism, Genetic; Ribavirin; Treatment Failure | 2014 |
Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Vertical transmission of hepatitis C virus: a tale of multiple outcomes.
Topics: Antiviral Agents; Child; Coinfection; Evolution, Molecular; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pregnancy; Pregnancy Complications, Infectious; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.
Topics: Animals; Coinfection; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptor, Interferon alpha-beta; Ribavirin; Signal Transduction | 2014 |
Characteristics of the cellular immune response in HIV/HCV patients with hemophilia during peginterferon/ribavirin therapy in southern China.
Topics: Adult; Antiviral Agents; China; Cytokines; Enzyme-Linked Immunospot Assay; Female; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Polymorphism, Single Nucleotide; Ribavirin; Young Adult | 2014 |
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 2014 |
Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Topics: Adult; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2014 |
Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; Coinfection; DNA, Viral; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Viral Load | 2014 |
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load | 2013 |
[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2013 |
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Ribavirin | 2014 |
Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; HIV Infections; Humans; Interferon-alpha; Liver; Male; Middle Aged; Prospective Studies; Ribavirin; Viral Load; Young Adult | 2015 |
European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; DNA, Mitochondrial; Female; Genotype; Haplotypes; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin; Spain; White People | 2014 |
OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2014 |
Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Diseases; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Survival Rate; Transplant Recipients; Treatment Outcome; Young Adult | 2014 |
Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
Topics: Adult; Aged; Antiviral Agents; Biological Availability; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; Young Adult | 2014 |
Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Topics: Antiviral Agents; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.
Topics: Adult; Aged; Aged, 80 and over; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; RNA, Viral | 2014 |
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
Topics: Adult; Antiviral Agents; Austria; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2014 |
Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Recurrence; Ribavirin; Sequence Analysis, RNA; Treatment Failure; Viral Proteins | 2015 |
HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Practice Guidelines as Topic; Ribavirin | 2014 |
Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin | 2014 |
Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukin-23; Leukocytes, Mononuclear; Male; Middle Aged; Receptor, Interferon alpha-beta; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Severe acute hepatitis E in an HIV infected patient: Successful treatment with ribavirin.
Topics: Adult; Alanine Transaminase; Bilirubin; CD4 Lymphocyte Count; Hepatitis Antibodies; Hepatitis E; HIV Infections; Humans; Immunocompromised Host; Liver Function Tests; Male; Prothrombin Time; Ribavirin; RNA, Viral; Viral Load | 2014 |
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; beta 2-Glycoprotein I; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2014 |
HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study.
Topics: Acute Disease; Adult; Asian People; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Ribavirin | 2014 |
CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.
Topics: Adult; Anti-HIV Agents; Cell Proliferation; Coinfection; Female; Hepatitis A Virus Cellular Receptor 2; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Male; Membrane Proteins; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Outcome | 2014 |
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.
Topics: Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; PPAR gamma; Retrospective Studies; Ribavirin; RNA, Viral; Time; Treatment Outcome; Viral Load | 2014 |
Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin; Survival Analysis; Viral Load | 2015 |
[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Immunocompromised Host; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sexually Transmitted Diseases; Spain | 2015 |
Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Does HIV remain a risk factor for achieving sustained virologic response under direct acting antiviral-based modern hepatitis C virus therapy?
Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2014 |
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Predictive Value of Tests; Ribavirin; RNA, Viral; Viral Load | 2014 |
Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
Topics: Adult; Alleles; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Coinfection; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-7; Male; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.
Topics: Gene Expression Profiling; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; MicroRNAs; Ribavirin | 2014 |
Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome | 2014 |
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Topics: Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antiviral Agents; Body Mass Index; Coinfection; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; Odds Ratio; Polymorphism, Single Nucleotide; Proteins; Ribavirin | 2014 |
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2015 |
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2015 |
[Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].
Topics: Adult; Antiviral Agents; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load | 2014 |
New kids on the block--step by step to an ideal HCV therapy.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides | 2015 |
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.
Topics: Antiviral Agents; Coinfection; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Topics: Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Veterans | 2015 |
Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Pulmonary; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Ribavirin | 2014 |
Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals.
Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Uridine Monophosphate | 2015 |
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
PHOTON-2: hope for patients with HIV and HCV co-infection?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Topics: Adult; Aging; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Toll-Like Receptor 3 | 2015 |
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients.
Topics: Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Spain; Tertiary Care Centers | 2015 |
Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Topics: Acute-Phase Proteins; Adult; Anti-HIV Agents; Aspartate Aminotransferases; Biomarkers; Carrier Proteins; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Kinetics; Lipopolysaccharide Receptors; Lipopolysaccharides; Male; Membrane Glycoproteins; Middle Aged; Retrospective Studies; Ribavirin; Solubility; Time Factors; Treatment Outcome | 2015 |
High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Cohort Studies; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin | 2015 |
A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; London; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2015 |
HCV/HIV Coinfection: A New Treatment Paradigm.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Ribavirin; Uridine Monophosphate | 2015 |
Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.
Topics: Antiviral Agents; Coinfection; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Ritonavir | 2015 |
Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.
Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2015 |
Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Ribavirin; Simeprevir; Sofosbuvir; Substance Withdrawal Syndrome | 2015 |
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
Topics: Adult; Antiviral Agents; Australia; Canada; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load | 2015 |
Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Cohort Studies; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Time Factors | 2015 |
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Spain; Thrombocytopenia; Treatment Outcome; Viral Load | 2015 |
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin; Spain; Treatment Outcome | 2015 |
Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Human T-lymphotropic virus 2; Humans; Interferon-alpha; Interleukin-6; Male; Middle Aged; Ribavirin; RNA, Viral | 2015 |
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Personality Disorders; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Young Adult | 2015 |
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sustained Virologic Response | 2015 |
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
Topics: Antiviral Agents; Coinfection; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load | 2016 |
Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
Topics: Adult; Antiviral Agents; Chemokine CXCL12; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Delivery of Health Care; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Diseases; Male; Middle Aged; Patient Acceptance of Health Care; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2016 |
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; Coinfection; Female; Gene Expression Regulation, Viral; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2016 |
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Odds Ratio; Prospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2015 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases.
Topics: Antiviral Agents; Coinfection; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin | 2016 |
Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin; Treatment Outcome | 2016 |
Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
Topics: Adult; Aged; Ambulatory Care Facilities; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; Treatment Outcome; United States | 2016 |
IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Coinfection; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukin-15; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Viral Load | 2016 |
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Platelet Count; Receptors, KIR; Ribavirin; Thrombocytopenia | 2017 |
Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
Topics: Adult; Antiviral Agents; Canada; Cohort Studies; Coinfection; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin | 2016 |
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir | 2016 |
Persisting hepatitis E virus infection leading to liver cirrhosis despite recovery of the immune system in an HIV-infected patient.
Topics: Antiviral Agents; DNA, Viral; Hepatitis E; Hepatitis E virus; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin | 2016 |
Double Filtration Plasmapheresis in Treatment of Patients With Co-Infection of Hepatitis C and Human Immunodeficiency Virus.
Topics: Adult; Antiviral Agents; Coinfection; Combined Modality Therapy; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
[Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Topics: Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunotherapy; Interferon-alpha; Male; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Standard of Care; Sustained Virologic Response; Treatment Outcome; Viral Load | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Georgia (Republic); Hepatitis C; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Retrospective Studies; Ribavirin; Tuberculosis, Pulmonary | 2016 |
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin | 2016 |
Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Fatigue; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Linear Models; Male; Middle Aged; Multivariate Analysis; Recovery of Function; Ribavirin; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Viral Load | 2016 |
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure | 2016 |
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Topics: Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2017 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
From current status to optimization of HCV treatment: Recommendations from an expert panel.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies, Medical; Viral Load | 2016 |
IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2016 |
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Longitudinal Studies; Male; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2016 |
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2017 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hong Kong; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cognitive Dysfunction; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Neuropsychological Tests; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2017 |
Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients?
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mortality; Prognosis; Ribavirin; RNA, Viral; Survival Analysis; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2017 |
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Mutation; Pilot Projects; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans | 2017 |
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Topics: Adult; Antiviral Agents; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Risk Assessment; RNA, Viral; Spain; Treatment Failure; Viral Load | 2008 |
Peginterferon monotherapy for the treatment of acute hepatitis C in HIV-coinfected patients.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2008 |
Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Demography; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.
Topics: Adult; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; ROC Curve; Serum; Treatment Outcome | 2008 |
HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Evolution, Molecular; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2009 |
Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Plasma; Ribavirin; Viral Proteins | 2008 |
HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.
Topics: Adult; Antiviral Agents; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Bilirubin; Drug Interactions; Female; Glucuronosyltransferase; Hepacivirus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ribavirin | 2008 |
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; United States | 2009 |
Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Treatment Outcome | 2008 |
Severe pruritus after completing pegylated interferon for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hand; Hepatitis C; HIV Infections; Humans; Interferons; Middle Aged; Polyethylene Glycols; Porphyria Cutanea Tarda; Pruritus; Ribavirin; Severity of Illness Index; Time Factors | 2008 |
Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
SEN Virus infection in HIV/HCV coinfected patients.
Topics: Adult; Antiviral Agents; Comorbidity; DNA Virus Infections; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Torque teno virus; Virus Replication | 2008 |
Viral-associated immune thrombocytopenic purpura.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Bisexuality; Hemorrhage; Hepacivirus; Hepatitis C; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Ribavirin; Risk Factors; Substance Abuse, Intravenous | 2008 |
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Patient Compliance; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Human immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history and the situation in China.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; China; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Australia; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Longitudinal Studies; Male; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Viral Load | 2008 |
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polypharmacy; Recombinant Proteins; Ribavirin; Sensation Disorders; Thyroiditis, Autoimmune; Thyroxine | 2009 |
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Body Mass Index; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
Topics: Antiviral Agents; Diabetes Mellitus; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2009 |
[ANRS HC 02 RIBAVIC: histo-pathological impact].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
[ANRS HC 02 RIBAVIC: from multicenter trial to daily practice].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Comorbidity; Drug Therapy, Combination; France; Government Agencies; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
[ANRS HC 02 RIBAVIC: from multicenter trial to daily practice. Conclusions].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Multicenter Studies as Topic; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
[Treatment of chronic hepatitis C in HIV-infected patients].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Congresses as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2009 |
[HIV-HCV co-infection: where are we now?].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Comorbidity; France; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Interferons; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2009 |
Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; HIV Infections; Humans; Interferons; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome | 2009 |
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2009 |
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2009 |
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Ribavirin; Treatment Outcome | 2009 |
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Cohort Studies; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2009 |
Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins; Young Adult | 2009 |
High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes; Viral Load; Young Adult | 2009 |
Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort.
Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon Type I; Luxembourg; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Registries; Remission, Spontaneous; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2009 |
CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients.
Topics: Adult; Antigens, CD; Antiviral Agents; B-Lymphocytes; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Longitudinal Studies; Lymphocyte Subsets; Male; Ribavirin; RNA, Viral; T-Lymphocytes; Tetraspanin 28; Viral Load | 2010 |
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Topics: Acute Disease; Adult; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Seroepidemiologic Studies; Substance-Related Disorders; Treatment Outcome | 2010 |
Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Blood Glucose; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Hypercholesterolemia; Hyperglycemia; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Lipodystrophy; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Triglycerides; Viral Load | 2009 |
Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2009 |
HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment.
Topics: Adult; Ambulatory Care Facilities; Antiviral Agents; Feasibility Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Sweden; Treatment Outcome | 2009 |
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2010 |
Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Chemokine CCL11; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Plasma; Retrospective Studies; Ribavirin; Treatment Outcome | 2010 |
[Protocol for the antiviral therapy of hepatitis C].
Topics: Algorithms; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin | 2010 |
Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Up-Regulation | 2010 |
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention | 2010 |
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Treatment of HIV-HCV and HBV-HCV co-infection].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin | 2005 |
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Treating hepatitis C in patients with cirrhosis: the effort is worth it.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; Treatment Outcome | 2010 |
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Spain; Treatment Outcome | 2010 |
Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.
Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV Seropositivity; Humans; Incidence; Interferons; Male; Population Dynamics; Prevalence; Ribavirin; RNA, Viral; Substance Abuse, Intravenous | 2011 |
Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Gene Expression Regulation; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; L-Lactate Dehydrogenase; Lactic Acid; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally.
Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
Topics: Adult; Antiviral Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2010 |
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Cohort Studies; Elasticity; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2010 |
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins | 2010 |
Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Monitoring; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Antibodies; HIV Core Protein p24; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Envelope Proteins; Viral Nonstructural Proteins | 2010 |
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome | 2010 |
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load | 2010 |
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.
Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Male; Middle Aged; Polymorphism, Genetic; Receptors, Tumor Necrosis Factor, Member 25; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin | 2010 |
Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
Topics: Adult; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Ribavirin; ROC Curve; Viral Load | 2010 |
Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Cohort Studies; Comorbidity; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Netherlands; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2011 |
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
Topics: Antiviral Agents; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Viral Load | 2010 |
The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients.
Topics: Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
Topics: Antiviral Agents; Black People; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Models, Theoretical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Serum; South America; Viral Load; White People | 2011 |
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Cross-sectional epidemiology of hepatitis C virus detection and treatment in HIV-infected patients.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Educational Status; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Records; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Spain; Statistics, Nonparametric | 2011 |
Sustained virologic response decreases serum markers of angiogenesis, inflammation, and fibrosis in HIV/HCV-coinfected patients on hepatitis C virus therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neovascularization, Pathologic; Retrospective Studies; Ribavirin | 2011 |
HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2011 |
Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Biomarkers; E-Selectin; Endothelial Cells; Female; Hepatitis C; HIV Infections; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Male; Middle Aged; P-Selectin; Receptors, Tumor Necrosis Factor, Type I; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Fas Ligand Protein; fas Receptor; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome | 2011 |
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Carrier Proteins; Catalysis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2011 |
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2011 |
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Zidovudine | 2011 |
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin | 2011 |
Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Female; Genotype; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Predictive Value of Tests; Receptors, LDL; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2011 |
Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Vitamin D; Vitamin D Deficiency | 2011 |
Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
Topics: Adult; Antiviral Agents; Atherosclerosis; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Sustained viral response after only 6 weeks of peginterferon and ribavirin treatment for acute hepatitis C in a HIV-1-infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study].
Topics: Adult; Antiviral Agents; Comorbidity; Contraindications; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Refusal to Treat; Ribavirin; Spain; Treatment Refusal | 2011 |
Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Coinfection; Depression; Drug Therapy, Combination; Ethanol; Female; France; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Medication Adherence; Middle Aged; Prospective Studies; Ribavirin; Socioeconomic Factors; Substance Abuse, Intravenous; Surveys and Questionnaires | 2012 |
[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Ribavirin; Zidovudine | 2012 |
Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.
Topics: Adult; Antiviral Agents; Coffee; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2012 |
Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drug Interactions; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Serine Proteases; Serine Proteinase Inhibitors; Viral Proteins | 2011 |
HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Virus Replication | 2011 |
Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2011 |
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Retrospective Studies; Ribavirin; Spain; Treatment Failure; Viral Load | 2011 |
Treatment of chronic hepatitis E in a patient with HIV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis E; HIV Infections; Humans; Immunocompromised Host; Interferon-alpha; Male; Middle Aged; Ribavirin | 2011 |
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Plasma; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
Topics: Adult; Ambulatory Care Facilities; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Program Evaluation; Recombinant Proteins; Referral and Consultation; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2011 |
Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Assessment | 2011 |
IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Coinfection; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil.
Topics: Adult; Antiviral Agents; Brazil; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Viral Load | 2012 |
Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Cell Line; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Lopinavir; Male; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Saquinavir; Tissue Inhibitor of Metalloproteinase-2; United Kingdom; Viral Load | 2011 |
Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Coinfection; Drug Monitoring; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2012 |
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Topics: Adult; Algorithms; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Cluster Analysis; Conserved Sequence; eIF-2 Kinase; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Phosphorylation; Phylogeny; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Serum; Viral Envelope Proteins | 2012 |
Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukin-6; Interleukin-9; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Treatment Failure; Viral Load | 2012 |
Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Immunoenzyme Techniques; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin | 2012 |
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Topics: Acyclovir; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Palatine Tonsil; Protease Inhibitors; Ribavirin; T-Lymphocytes; Tissue Culture Techniques; Zidovudine | 2012 |
The influence of treatment with pegylated interferon-alfa and ribavirin on neutrophil function and death in patients with HIV/HCV coinfection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiviral Agents; Apoptosis; CD4 Lymphocyte Count; Coinfection; Female; Flow Cytometry; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Neutrophil Activation; Neutrophils; Reactive Oxygen Species; Ribavirin; Viral Load | 2012 |
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
Topics: Antiviral Agents; Genotype; Haplotypes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin | 2012 |
Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection.
Topics: Abducens Nerve Diseases; Adult; Antiviral Agents; Eye; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Muscle, Skeletal; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Topics: Adult; Bacteria; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coinfection; Demography; Female; Fibrosis; Hepatitis C, Chronic; HIV Infections; HLA-DR Antigens; Humans; Interferon-alpha; Lipopolysaccharide Receptors; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Solubility; Treatment Outcome | 2012 |
LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, LDL; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
Topics: Adult; Antiviral Agents; Erythrocytes; Hemoglobins; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
Topics: Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Superinfection; Viral Load | 2012 |
The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Bacterial Infections; CD4-Positive T-Lymphocytes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferons; Leukocyte Count; Male; Middle Aged; Neutrophils; Opportunistic Infections; Ribavirin | 2012 |
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Factors | 2012 |
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Health Care Costs; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Homosexuality, Male; Humans; Immunoassay; Interferons; Life Expectancy; Liver Function Tests; Male; Mass Screening; Middle Aged; Protease Inhibitors; Ribavirin | 2012 |
Comparison of hepatitis C virus treatment between incarcerated and community patients.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antiviral Agents; Confidence Intervals; Databases, Factual; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Prisoners; Recombinant Proteins; Residence Characteristics; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Factors; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2012 |
Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Middle Aged; Prospective Studies; Ribavirin | 2012 |
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
Topics: Adult; Anemia; Antiviral Agents; Coinfection; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Ribavirin; Treatment Outcome | 2012 |
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Interferons; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Ribavirin; Spain; Treatment Outcome; Viral Load | 2012 |
Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Topics: 5' Untranslated Regions; Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Treatment Failure; Viral Envelope Proteins; Viral Nonstructural Proteins | 2012 |
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
New approaches to the management of hepatitis C in haemophilia in 2012.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin | 2012 |
Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.
Topics: Adult; Antiviral Agents; Computational Biology; Down-Regulation; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Molecular Diagnostic Techniques; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Up-Regulation | 2012 |
[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center].
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2012 |
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Socioeconomic Factors; Treatment Outcome; Young Adult | 2013 |
Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2012 |
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Topics: Adult; Anti-Retroviral Agents; Cardiac Output; CD4 Lymphocyte Count; Coinfection; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Interferon-alpha; Liver; Liver Cirrhosis; Lung; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viremia | 2012 |
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load | 2012 |
Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man.
Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
The effect of unsuccessful treatment with peginterferon and ribavirin on the liver fibrosis course of HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2013 |
Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Cytokines; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Viral Load | 2013 |
Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Vitamin D; Vitamin D Deficiency | 2013 |
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome | 2013 |
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Platelet Count; Polyethylene Glycols; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoietin | 2013 |
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.
Topics: Adult; Antiviral Agents; Black or African American; Black People; Chemokine CXCL10; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2013 |
[Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guideline Adherence; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Patient Care Team; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; RNA, Viral; Standard of Care; Treatment Outcome; Viral Load; Young Adult | 2013 |
Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Alanine Transaminase; Cohort Studies; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Proportional Hazards Models; Ribavirin | 2013 |
Interferon and ribavirin for hepatitis C.
Topics: CD4 Lymphocyte Count; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Function Tests; Male; Ribavirin | 2000 |
Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C.
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
Topics: Anemia; Anti-HIV Agents; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin | 2001 |
Advisory panel: expand hepatitis therapy to HIV/AIDS patients.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; United States | 2002 |
Managing hepatitis C infection in HIV-positive patients.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Ribavirin; United States | 2000 |
[Treatment of hepatitis C: advances and consensus].
Topics: Aged; Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Consensus Development Conferences as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Paris; Research; Ribavirin; Risk Factors; Substance-Related Disorders | 2002 |
[Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients].
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Pilot Projects; Ribavirin; Treatment Outcome | 2002 |
Weight loss in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Mitochondria; Ribavirin; Weight Loss | 2002 |
Use of antiviral therapy in patients with hepatitis C.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Interactions; Hepatitis C; HIV Infections; Humans; Interferons; Retrospective Studies; Ribavirin | 2002 |
Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Urban Health; Urban Population | 2003 |
[Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2003 |
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
Topics: Anti-HIV Agents; Cells, Cultured; Didanosine; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Interferon-alpha; Ribavirin; Virus Replication | 2003 |
Current issues in hepatitis C, HIV co-infection discussed at lunch and learn.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; United States | 2002 |
Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence.
Topics: Anti-HIV Agents; Antiviral Agents; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Mental Disorders; Ribavirin; Substance-Related Disorders; Treatment Refusal; Viral Load | 2003 |
New warning for ddI.
Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Interactions; Drug Labeling; Hepatitis C; HIV Infections; Humans; Ribavirin | 2002 |
Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hemophilia A; Hepatitis C; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Interferons; Ribavirin | 2003 |
Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load | 2003 |
[Increasing chances. Effective HCV therapy lowers mortality of HIV infection].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cause of Death; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate | 2003 |
Anemia in the treatment of hepatitis C virus infection.
Topics: Anemia; Antiviral Agents; Epoetin Alfa; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo.
Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Synergism; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-gamma; Ribavirin | 2003 |
High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Didanosine; Female; Hepatitis C; HIV Infections; Humans; Incidence; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Proportional Hazards Models; Ribavirin | 2004 |
Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2004 |
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Mutation; Pilot Projects; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2004 |
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2004 |
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Infections; Enzyme-Linked Immunosorbent Assay; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferon-alpha; Lymphocyte Activation; Ribavirin; Th1 Cells | 2004 |
Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Nucleoside analogues and mitochondrial toxicity.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Mitochondria; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine | 2004 |
Treating HCV infection in HIV/HCV-coinfected patients.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Pegasys-Copegus combination treats both HIV and hepatitis C.
Topics: Antiviral Agents; Drug Combinations; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
[HIV/HCV coinfection: 40% of patients can successfully be treated].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Hepatitis C treatment eligibility in an urban population with and without HIV coinfection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Hepatitis C; HIV Infections; Humans; Illinois; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Patient Selection; Polyethylene Glycols; Poverty Areas; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Urban Health Services | 2004 |
Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2004 |
Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
[HIV/HCV double infection: combination is a clear therapy option].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Treating hepatitis C in "difficult-to-treat" patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin.
Topics: Adult; Cataract; Color Vision Defects; Eye Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Vision Disorders | 2004 |
[Progress in the treatment of hepatitis B and C co-infection in HIV patients].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate | 2004 |
[APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
[Eliminating the gray zone. What can be done in normal ALT values?].
Topics: AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
[Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
Topics: Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Cardiovascular Diseases; Depression; Female; Follow-Up Studies; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2004 |
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Topics: Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
[Sexual transmission of hepatitis C in homosexual men].
Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Lymphogranuloma Venereum; Male; Middle Aged; Netherlands; Prevalence; Proctitis; Ribavirin; Risk Factors; Sexual Behavior; Sexually Transmitted Diseases, Viral | 2004 |
[Epidemiological, clinical and therapeutical aspects of HIV/HCV coinfection in a series of HIV seropositive Umbrian patients].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Italy; Liver; Male; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Substance-Related Disorders; Treatment Outcome | 2004 |
Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
PegIFN/ribavirin during acute HCV coinfection.
Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2004 |
Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Researchers identify better hepatitis C treatment for people with HIV.
Topics: Antiviral Agents; Drug Carriers; Hepatitis C; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin.
Topics: Adult; Antiviral Agents; Cohort Studies; Eligibility Determination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2005 |
HIV and hepatitis C virus co-infection.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Ribavirin | 2005 |
Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat.
Topics: Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[Hepatitis C and HIV in Spanish prisons].
Topics: Adult; Antiviral Agents; Comorbidity; Female; Hepatitis C, Chronic; HIV Infections; HIV Seroprevalence; Hospitalization; Hospitals, Public; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prisoners; Prisons; Recombinant Proteins; Ribavirin; Seroepidemiologic Studies; Spain; Substance Abuse, Intravenous | 2005 |
Delivering care to injection drug users coinfected with HIV and hepatitis C virus.
Topics: Adult; Antiviral Agents; Delivery of Health Care, Integrated; Eligibility Determination; Female; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Rhode Island; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2005 |
Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Unsafe Sex | 2005 |
[Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2005 |
My personal experience in being HCV/HIV co-infected & how I cured hepatitis C.
Topics: Anecdotes as Topic; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
HIV and hepatitis co-infection: a consensus for treatment?
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Vaccines; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Hepatitis drug gets approval for coinfection treatment.
Topics: Antiviral Agents; Drug Approval; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 2005 |
Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mitochondrial Diseases; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Linear Models; Male; Ribavirin | 2005 |
Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; DNA, Mitochondrial; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Polyethylene Glycols; Ribavirin | 2005 |
HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Hyperglycemia; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Multivariate Analysis; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2005 |
Workshop report treating hepatitis C in HIV-infected patients: where are we now?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; United States | 2005 |
Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2005 |
Delaying HCV treatment in HIV-positive patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2005 |
[Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2005 |
Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients.
Topics: Demography; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Male; Prisoners; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2005 |
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2005 |
[Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of the APRICOT study].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load | 2005 |
Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report.
Topics: Adult; Antiviral Agents; Depression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2005 |
[Co-infection with HIV-hepatitis C virus].
Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Hepatitis C; HIV Infections; Humans; Ribavirin | 2005 |
[Treatment of the side effects of antiviral therapy].
Topics: Antiviral Agents; Hepatitis, Viral, Human; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2005 |
[Treatment of chronic hepatitis C in patients with HIV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2005 |
Hepatitis C and didanosine: risk of lactic acidosis.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Contraindications; Didanosine; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2005 |
Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2005 |
FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
Topics: Antiviral Agents; Contraindications; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration; Viral Load | 2005 |
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Recombinant Proteins; Retrospective Studies; Ribavirin; Sexual Behavior; Sexually Transmitted Diseases, Viral; Treatment Outcome | 2006 |
HCV infection in the setting of HIV: prevalence, disease, treatment.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin | 2006 |
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
[Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic ant therapeutic difficulties].
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Hepatitis, Autoimmune; HIV Infections; Humans; Liver Function Tests; Ribavirin | 2006 |
Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2006 |
Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Blood Cell Count; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Switzerland | 2006 |
[Prevalence of hepatitis C virus among HIV-infected patients in Area 2 of Madrid].
Topics: Adult; Alcohol Drinking; Antiviral Agents; CD4 Lymphocyte Count; Comorbidity; Cross-Sectional Studies; Drug Utilization; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Outpatients; Prevalence; Ribavirin; Risk Factors; Seroepidemiologic Studies; Sexual Behavior; Spain; Substance Abuse, Intravenous; Surveys and Questionnaires; Urban Population; Viral Load | 2006 |
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA; Treatment Outcome | 2006 |
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Topics: Age Distribution; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2006 |
Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient.
Topics: Adult; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2006 |
[Selection for treatment of hepatitis C co-infected patients for ].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Patient Selection; Polyethylene Glycols; Ribavirin | 2006 |
[Primer treatment of acute and chronic hepatitis C].
Topics: Acute Disease; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient.
Topics: Adult; Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lymphadenitis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Tuberculosis, Lymph Node | 2006 |
Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature.
Topics: Adult; Antiviral Agents; Biopsy; Comorbidity; Drug Therapy, Combination; Fatal Outcome; Giant Cells; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hospitals, Special; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Retrospective Studies; Ribavirin; RNA, Viral; Spain | 2006 |
Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin.
Topics: Adult; Antiviral Agents; Crohn Disease; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretro
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Follow-Up Studies; Gene Rearrangement, T-Lymphocyte; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Common Antigens; Male; Polyethylene Glycols; Prospective Studies; Receptors, Antigen, T-Cell; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Thymus Gland; Treatment Outcome | 2006 |
Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.
Topics: Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Department of Veterans Affairs; Veterans | 2006 |
[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Prisoners; Prisons; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Spain; Substance Abuse, Intravenous; Treatment Outcome | 2006 |
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin; Treatment Refusal | 2007 |
[Early virologic response value as predictive factor of sustained virologic response to treatment with interferon alpha-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection].
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2006 |
[Applicability of hepatitis C virus kinetics in patients co-infected with HIV].
Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Weight Loss | 2007 |
Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Viral Load | 2007 |
Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies.
Topics: Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Activation | 2007 |
Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
Topics: Adolescent; Adult; Aged; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Black People; Cell Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Protease Inhibitors; Recombinant Proteins; Reticulocytes; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors; Treatment Outcome; White People; Zidovudine | 2007 |
Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.
Topics: Adult; Antiviral Agents; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2007 |
Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome | 2007 |
[Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Acquired factor VIII inhibitor in an HIV-infected patient after treatment with pegylated interferon-alpha 2a and ribavirin.
Topics: Adult; Antiviral Agents; Factor VIII; Hemorrhage; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Asia; Australia; Child; Communicable Disease Control; Genotype; Hemophilia A; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Immunoenzyme Techniques; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Molecular Diagnostic Techniques; Reagent Kits, Diagnostic; Ribavirin; RNA, Viral; Thalassemia; Treatment Outcome; Viral Load | 2007 |
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
Topics: Anti-HIV Agents; Antiviral Agents; Bilirubin; Chi-Square Distribution; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2007 |
Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases; White People | 2007 |
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.
Topics: Administration, Oral; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
Topics: Adult; Antiviral Agents; Area Under Curve; Drug Interactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Phosphorylation; Reverse Transcriptase Inhibitors; Ribavirin; Zidovudine | 2007 |
Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-alpha 2b and ribavirin.
Topics: Adult; Antiviral Agents; Base Sequence; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes | 2007 |
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2007 |
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Replication | 2007 |
Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.
Topics: Antiviral Agents; Biomarkers; Child; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Poisson Distribution; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2007 |
Highlights of the third international workshop on HIV and hepatitis coinfection.
Topics: Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C; Hepatitis, Viral, Human; HIV Infections; Humans; Interferons; Ribavirin | 2007 |
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Improved cognitive function as a consequence of hepatitis C virus treatment.
Topics: Adult; Antiviral Agents; Cognition Disorders; Cognitive Behavioral Therapy; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome | 2007 |
Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Female; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Liver Diseases; Male; Necrosis; Ribavirin; RNA, Viral; Transaminases; Viral Load | 2007 |
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Disease Progression; Female; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Interferons; Liver; Logistic Models; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Ribavirin | 2007 |
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Biomarkers; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Hospitals; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2008 |
Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.
Topics: Administration, Oral; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Virus Replication | 2008 |
Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
Topics: Adult; Anger; Anti-Retroviral Agents; Antiviral Agents; Anxiety Disorders; Cross-Sectional Studies; Female; France; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Records; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2008 |
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Survival Rate; Time Factors | 2008 |
Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeks.
Topics: Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load | 2008 |
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Viral Load | 2007 |
Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hemorrhage; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Israel; Liver; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2008 |
[Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection].
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin | 2007 |
Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2008 |
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
Topics: Adult; Antiviral Agents; Female; Hemoglobins; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Plasma; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Spain; Thrombocytopenia; Zidovudine | 2007 |
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Prevalence; Ribavirin; Risk Factors | 2008 |
Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.
Topics: Cells, Cultured; Dendritic Cells; Flow Cytometry; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Recombinant Proteins; Ribavirin; Viremia | 2008 |
Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Immunophenotyping; Immunotherapy; Interferons; Interleukin-2; Killer Cells, Natural; Male; Middle Aged; Polyethylene Glycols; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome | 2008 |
Oral lesions in HIV and HCV co-infected individuals in HAART era.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antiretroviral Therapy, Highly Active; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Coitus; Disease Susceptibility; Feeding Behavior; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mouth Diseases; Mouthwashes; Ribavirin; Risk Factors; Smoking; Substance Abuse, Intravenous; Time Factors; Viral Load; Young Adult | 2008 |
[Diabetes mellitus during interferon therapy].
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Autoimmune; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.
Topics: Adult; Antiviral Agents; Blood Glucose; Drug Administration Schedule; Fasting; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Homeostasis; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy.
Topics: Adult; Antiviral Agents; Case-Control Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Statistics, Nonparametric; Viral Load | 2008 |
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; CD4 Lymphocyte Count; Cyclosporine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Tacrolimus; Treatment Outcome; Viral Load | 2008 |
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; CD56 Antigen; Female; Flow Cytometry; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia | 2008 |
Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection.
Topics: Adult; Drug Therapy, Combination; HIV Infections; Humans; Immunoglobulins; Male; Measles; Pneumonia; Ribavirin | 1993 |
[Infectious diseases in 1998].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Bacterial Vaccines; Blood Donors; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferons; Lamivudine; Middle Aged; Multicenter Studies as Topic; Pneumonia, Pneumococcal; Randomized Controlled Trials as Topic; Ribavirin; Streptococcus pneumoniae; Transfusion Reaction; Zidovudine | 1999 |
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy, Needle; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin | 1999 |
Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin | 1998 |
[Treatment and prevention of hepatitis C].
Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin | 2000 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Aged; Amantadine; Animals; Anti-HIV Agents; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Enzyme Inhibitors; Famciclovir; Ganciclovir; Guanidines; Guanine; Herpes Simplex; Herpes Zoster; History, 18th Century; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Lamivudine; Neuraminidase; Oseltamivir; Pyrans; Rats; Ribavirin; Sialic Acids; Teratogens; Valacyclovir; Valine; Zanamivir | 1999 |
Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Nucleosides; Ribavirin | 2000 |
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Topics: Adult; Anemia; Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymerase Chain Reaction; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2000 |
Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients.
Topics: Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2000 |
[Efficacy and safety of combination therapy with interferon-alpha and ribavirin in patients with chronic hepatitis C coinfected with human immunodeficiency virus].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2000 |
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Mitochondrial Myopathies; Ribavirin | 2001 |
Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and ribavirin combination therapy.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral | 2001 |
Very few hepatitis trials recruiting.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Guanine; Hepatitis B; HIV Infections; Humans; Interferon-alpha; Patient Selection; Ribavirin | 1998 |
Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Hepatitis C and HIV: ribavirin plus interferon study recruiting.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Patient Selection; Ribavirin; United States | 1998 |
Treating hepatitis C: a clinician's perspective. Interview by Bob Roehr.
Topics: Antiviral Agents; Biopsy; Body Weight; Dose-Response Relationship, Drug; Hepatitis C; HIV Infections; Interferon Type I; Liver; Liver Transplantation; Recombinant Proteins; Ribavirin | 1998 |
Hepatitis C: new treatment overview.
Topics: Antiviral Agents; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Internet; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Evolving strategies to attack hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors | 1998 |
Soaring prices, soaring sales.
Topics: Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Interferon alpha-2; Interferon-alpha; Oxazines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; United States | 1998 |
Hepatitis C virus and HIV co-infection: a sleeping giant wakes.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 1999 |
Product information.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Resistance, Microbial; Hepatitis C; HIV Infections; Humans; Ribavirin | 1999 |
Opportunistic infections update.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver; Ribavirin | 1998 |
Ribavirin for hepatitis C: 80% price reduction available July 9?
Topics: Anti-HIV Agents; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin | 1999 |
Study results presented on interferon/ribavirin combination therapy.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States | 2001 |
Treatment of hepatitis C virus and HIV coinfection: the road less traveled.
Topics: Antiretroviral Therapy, Highly Active; Disease Management; Drug Therapy, Combination; Education, Continuing; Female; Hepatitis C; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Recombinant Proteins; Ribavirin | 2001 |
Combination reduces HCV load.
Topics: Clinical Trials as Topic; Drug Combinations; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States | 2001 |
HIV/HCV co-infection has treatment implications.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Practice Guidelines as Topic; Ribavirin | 2000 |
Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2002 |
Management issues in patients coinfected with hepatitis C virus and HIV.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Hepacivirus; Hepatitis A Vaccines; Hepatitis B Vaccines; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin; RNA, Viral; Vaccination | 2002 |
[Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2002 |
Needlestick transmission of hepatitis C.
Topics: Accidents, Occupational; Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Asthenia; Exanthema; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Internship and Residency; Lamivudine; Needlestick Injuries; Nelfinavir; Occupational Exposure; Physicians; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Zidovudine | 2002 |
Diagnosis and management of the HCV/HIV-coinfected patient.
Topics: Anti-HIV Agents; Biopsy; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin | 2002 |
HIV and hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Hepatitis A Vaccines; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Recombinant Proteins; Ribavirin | 2002 |
[Hepatitis C and HIV coinfection. Current aspects of therapy].
Topics: Anti-HIV Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Survival Rate | 2002 |
HIV & hepatitis C: treatment.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Ribavirin for HIV--continuing smoke, not much fire.
Topics: Clinical Trials as Topic; HIV Infections; Humans; Ribavirin | 1991 |
Ribavirin and HIV.
Topics: Clinical Trials as Topic; HIV Infections; Humans; Research Design; Ribavirin | 1991 |
Ribavirin for HIV.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Ribavirin | 1991 |
Ribavirin: a role in HIV infection.
Topics: HIV Infections; Humans; Ribavirin; Ribonucleosides | 1990 |
Ribavirin: a role in HIV infection?
Topics: Acquired Immunodeficiency Syndrome; HIV Infections; Humans; Research Design; Ribavirin; Ribonucleosides | 1990 |